Check for updates

OPEN ACCESS

EDITED BY Swati Patel, University of Colorado Anschutz Medical Campus, United States

REVIEWED BY Pietro Paolo Vitiello, IFOM - The FIRC Institute of Molecular Oncology, Italy Gianni Lazzarin, Abano Terme Hospital, Italy

*CORRESPONDENCE Shaneda Warren Andersen Snandersen@wisc.edu

RECEIVED 04 December 2023 ACCEPTED 16 April 2024 PUBLISHED 26 April 2024

CITATION

Lawler T, Parlato L and Warren Andersen S (2024) The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and metaanalysis. *Front. Oncol.* 14:1349572. doi: 10.3389/fonc.2024.1349572

COPYRIGHT

© 2024 Lawler, Parlato and Warren Andersen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The histological and molecular characteristics of early-onset colorectal cancer: a systematic review and meta-analysis

Thomas Lawler¹, Lisa Parlato² and Shaneda Warren Andersen^{1,2*}

¹School of Medicine and Public Health, Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States, ²School of Medicine and Public Health, Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, United States

Background: Early-onset colorectal cancer (CRC), defined as diagnosis before age 50, has increased in recent decades. Although more often diagnosed at advanced stage, associations with other histological and molecular markers that impact prognosis and treatment remain to be clarified. We conducted a systematic review and meta-analysis concerning the prevalence of prognostic and predictive tumor markers for early- vs. late-onset CRC, including oncogene mutations, microsatellite instability (MSI), and emerging markers including immune cells and the consensus molecular subtypes.

Methods: We systematically searched PubMed for original research articles published between April 2013–January 2024. Included studies compared the prevalence of tumor markers in early- vs. late-onset CRC. A meta-analysis was completed and summary odds ratios (ORs) with 95% confidence intervals (CIs) were obtained from a random effects model via inverse variance weighting. A sensitivity analysis was completed to restrict the meta-analysis to studies that excluded individuals with Lynch syndrome, a hereditary condition that influences the distribution of tumor markers for early-onset CRC.

Results: In total, 149 articles were identified. Tumors from early-onset CRC are less likely to include mutations in *KRAS* (OR, 95% CI: 0.91, 0.85-0.98), *BRAF* (0.63, 0.51-0.78), *APC* (0.70, 0.58-0.84), and *NRAS* (0.88, 0.78-1.00) but more likely to include mutations in *PTEN* (1.68, 1.04-2.73) and *TP53* (1.34, 1.24-1.45). After limiting to studies that excluded Lynch syndrome, the associations between early-onset CRC and *BRAF* (0.77, 0.64-0.92) and *APC* mutation (0.81, 0.67-0.97) were attenuated, while an inverse association with *PIK3CA* mutation was also observed (0.88, 0.78-0.99). Early-onset tumors are less likely to develop along the CpG Island Methylator Phenotype pathway (0.24, 0.10-0.57), but more likely to possess adverse histological features including high tumor grade (1.20, 1.15-1.25), and mucinous (1.22, 1.16-1.27) or signet ring histology (2.32, 2.08-2.57). A positive association with MSI status (1.31, 1.11-1.56) was also identified. Associations with immune markers and the consensus molecular subtypes are inconsistent.

Discussion: A lower prevalence of mutations in *KRAS* and *BRAF* is consistent with extended survival and superior response to targeted therapies for metastatic disease. Conversely, early-onset CRC is associated with aggressive histological subtypes and *TP53* and *PTEN* mutations, which may serve as therapeutic targets.

KEYWORDS

colorectal cancer, colon cancer, rectal cancer, early-onset, oncogenes, prognosis, molecular characteristics

1 Introduction

Colorectal cancer (CRC) is the second leading cause of cancer mortality in the United States (1). The incidence of CRC has steadily declined since the 1980s, largely attributed to greater uptake of colonoscopy screening by adults aged 50 years and older (2). Concurrently, the incidence of sporadic early-onset CRC, generally defined as CRC diagnosis before age 50 without an underlying hereditary cause, has significantly increased since the mid-1990s (2). Data from the Surveillance, Epidemiology, and End Results (SEER) program reflect a 2-3% annual increase in the incidence of early-onset CRC (3). The elevated incidence of earlyonset CRC may be explained by birth cohort effects where more recent birth cohorts have increased prevalence of obesity and type 2 diabetes, lower levels of physical activity, and more often consume western-style diets characterized by lower consumption of fruits and vegetables (4), as well as changes in the composition of the gut microbiome (2). While early-onset CRC may be caused by hereditary conditions defined by germline mutations in DNA mismatch-repair genes (i.e. Lynch syndrome) or in the tumor suppressor APC (i.e. familial adenomatous polyposis) (5), these inherited conditions account for a relatively small percentage of early-onset CRC and do not explain the increased prevalence observed in recent decades (2).

CRC is a heterogeneous disease and the clinicopathological and molecular characteristics of tumors may influence prognosis and response to treatment (6). Beyond tumor stage, multiple potential prognostic and predictive markers have been identified, including mutations in oncogenes such as *KRAS*, *BRAF*, *PIK3CA*, and *TP53*, histological subtypes including mucinous and signet ring carcinomas, and the microsatellite instability (MSI) phenotype (7). Further, several novel prognostic markers have recently been identified, including immune markers in the tumor microenvironment (8) and the CRC consensus molecular subtypes (9). It is anticipated that the continued characterization of molecular phenotypes in CRC will augment traditional clinical markers for therapeutic decision making and support the development of targeted approaches to treatment (10).


Given the increasing rate of early-onset CRC, recent publications have highlighted potential differences in the clinicopathological and molecular characteristics of tumors based on age of onset (11–14). However, it is currently unclear whether early-onset CRC is distinct from late-onset disease in terms of molecular characteristics and tumor developmental pathways (15). Understanding the molecular characteristics of early-onset CRC is necessary to guide the development of therapeutic approaches for this condition and to address underlying causes. Therefore, we have completed a systematic review and meta-analysis to comprehensively summarize the evidence linking early-onset CRC to differences in prognostic and predictive tumor markers, including oncogene mutations, histological subtypes, MSI status, as well as anti-tumor immunity and the consensus molecular subtypes.

2 Methods

2.1 Literature review

Articles for this systematic review were identified utilizing a Pubmed search incorporating PRISMA guidelines (16). Given the wide breadth of the topic and the limited number of relevant articles published prior to 2013, the search was limited to peer-reviewed, original research articles published in English from the last 10 years (April 2013 – April 2023), with relevant keywords and medical subject headings included in the title and/or abstract. The literature review was repeated in January 2024 to identify recently published articles. Specific biomarker terms to include in the literature search were identified from prior reviews, and the search terms "biomark*", "mark*", and "character*" were included to capture potentially novel prognostic markers. All search terms included for the literature review are displayed in Supplementary Table S1. Manuscripts were included that reported the prevalence of prognostic biomarkers in

Abbreviations: AACR, American Association for Cancer Research; APC, adenomatous polyposis coli; CI, confidence interval; CIMP, CpG island methylator phenotype; CMS, consensus molecular subtypes; COH, City of Hope (National Medical Center); CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MDACC, MD Anderson Cancer Center; MSI, microsatellite instability; MSKCC, Memorial Sloan Kettering Cancer Center; MSS, microsatellite stable; OR, odds ratio; SEER, Surveillance, Epidemiology, and End Results; TIL, tumor infiltrating lymphocytes.



was defined as \leq 60 years at diagnosis (or older).

CRC tumors separately for early- vs. late-onset disease. Articles were excluded if the prevalence of tumor clinicopathological or molecular biomarkers were not provided for participants with CRC (see Figure 1 flowchart), or if there was no comparison between early- vs. late-onset CRC (or if the comparison was limited to tumor stage or location only). Articles were also excluded that described hereditary CRC only (e.g. Lynch syndrome), site-specific metastases, or included non-CRC cancers in the analysis samples. For the purposes of this analysis, early-onset disease was defined as CRC diagnosed prior to age 50. To avoid misclassification of early- and late-onset CRC, we excluded papers where late-onset CRC was defined as \geq 40 years at diagnosis or younger, or where early-onset CRC was defined as \leq 60 years at diagnosis or older. Lastly, to limit sample overlap where possible, we excluded studies if there was evidence of complete overlap in sample and markers reported with a previously published study, or if a study reported the same outcome in a subsample of a previous study.

The systematic review and meta-analysis was limited to the following markers that have been shown associations with CRC survival and/or therapeutic response in CRC: oncogene mutations in *KRAS* (17–20), *NRAS* (17, 21, 22), *BRAF* (17, 19, 23, 24), *PIK3CA* (17, 25, 26), *PTEN* (27, 28), *TP53* (29), *APC* (30, 31), and *HER2* amplifications (32–34); histological phenotypes including high-grade tumors (35, 36) and mucinous (37, 38) or signet ring histology (38, 39); molecular carcinogenesis pathways including MSI (40) and the CpG island methylator phenotype (CIMP) (41); and novel tumor prognostic phenotypes including immune markers (42, 43) in the tumor microenvironment and the consensus

molecular subtypes (9, 44). Because it is well-established that early-onset CRC is associated with advanced tumor summary stage at diagnosis and rectal tumor location, these markers are not summarized in this review. The literature review was completed by two authors (T.L. and L.P) independently. Disagreements between reviewers were resolved by further review of the manuscript to determine whether the study included a comparison of tumor markers of interest between early- and lateonset CRC. The final decision to include a manuscript was made by the lead author. In total, 1,694 articles were identified from the literature search and 149 were eligible for review (Figure 1). For each study, the potential for bias was evaluated by the lead author using the Newcastle-Ottawa Scale adapted for cross-sectional studies (45). Pre-registration of the systematic review protocol was not performed.

2.2 Meta-analysis

From each eligible study, the number of mutant and wild-type tumors for each marker in early- and late-onset CRC was extracted by the lead author. Data extraction was completed in duplicate, and the results from the two extractions were compared to identify any errors or inconsistencies in the sample sizes, which were subsequently revised after further review of the original article. If these data were not available from the manuscript, sample sizes were requested from the corresponding author. One study was excluded for which we were unable to obtain the necessary sample sizes from each group (46). When necessary, sample sizes for separate age groups were combined to create a single category for early-onset and late-onset CRC. For most studies, age 45 or 50 at diagnosis was utilized as the threshold to distinguish early- vs. lateonset CRC, although occasionally other classifications were employed (see Supplementary S2). For each study, sample characteristics including overall sample size, country, tumor stage, sex, or other distinguishing features were also extracted. For each marker, an odds ratio (OR) and 95% confidence interval (CI) were calculated using a standard equation (47). For mutations in oncogenes KRAS, NRAS, BRAF, PIK3CA, PTEN, TP53, and APC, as well as MSI status and histological subtypes, meta-analyses were completed to compare the prevalence in tumors from earlyvs. late-onset CRC. Due to the wide variety of immune markers that have been reported, a meta-analysis was not attempted for the comparison of immune phenotypes in the tumor microenvironment. For each marker that was meta-analyzed, a pooled OR with 95% CI was obtained from a random effects model via inverse variance weighting. The random effects model was selected a priori, as between-study heterogeneity is plausible given variability in the definition of early-onset CRC, as well as differences in tumor location, race, nationality and stage between studies. The random effects meta-analysis is capable of providing unbiased estimates in the presence of heterogeneity and will generally provide more conservative estimates than the fixed-effects model (which assumes no between-study heterogeneity) (48). Heterogeneity was determined via the Cochrane's Q statistic and the I^2 statistic. Significant heterogeneity was defined as P <.05 for Cochrane's Q or $I^2 \ge 50\%$. To determine whether the meta-analysis estimates were influenced by a single study, a 'leave-one-out' sensitivity analysis was conducted for each marker. Because Lynch syndrome may influence the prevalence of tumor markers for individuals with early-onset CRC, a second sensitivity analysis was completed to limit the analysis to studies that specifically excluded individuals with Lynch syndrome or family history of CRC, or that restricted the sample to microsatellite stable tumors. All statistical tests were two-sided, with statistical significance defined using a threshold of P <.05. All meta-analyses were completed using Review Manager 5.4.1 from Cochrane.

3 Results

In total, 149 articles were reviewed that compared the prevalence of clinicopathological tumor markers in early- vs. lateonset CRC. All meta-analysis results are summarized in Table 1. Sample characteristics and references for all included studies are presented in Supplementary Table S2. Results of the bias assessment utilizing the Newcastle-Ottawa Scale are presented in Supplementary Table S4.

3.1 Oncogene mutations

The number of studies identified for the following markers is as follows: *KRAS* mutation (49); *BRAF* mutation (49); *NRAS* mutation

TABLE 1 Summary of meta-analysis results showing associations between early-onset colorectal cancer and the prevalence of tumor markers, compared to late-onset colorectal cancer.

	All studie	es (N = 150)		Studies that excluded individuals with Lynch syndrome ^a (N = 50)			
Marker	Number of studies	OR (95% CI)	P-value	Number of studies	OR (95% CI)	P-value	
KRAS mutation	54	0.91 (0.85-0.98)	.01	19	0.87 (0.80-0.95)	.002	
BRAF mutation	54	0.63 (0.51-0.78)	<.001	17	0.77 (0.64-0.92)	.004	
NRAS mutation	20	0.88 (0.78-1.00)	.06	6	0.89 (0.70-1.13)	.33	
APC mutation	19	0.70 (0.58-0.84)	<.001	7	0.81 (0.67-0.97)	.02	
TP53 mutation	20	1.34 (1.24-1.45)	<.001	8	1.40 (1.32-1.48)	<.001	
PTEN mutation	8	1.68 (1.04-2.73)	.04	3	2.81 (0.56-14.18)	.21	
PIK3CA mutation	21	0.95 (0.86-1.05)	.29	8	0.88 (0.78-0.99)	.03	
HER2 amplification	4	1.64 (0.86-3.14)	.13	0	N/A	N/A	
CIMP status	10	0.24 (0.10-0.57)	.001	7	0.41 (0.21-0.79)	.007	
MSI status	64	1.31 (1.11-1.56)	.002	20	1.37 (0.91-2.07)	.13	
High tumor grade	87	1.20 (1.15-1.25)	<.001	33	1.34 (1.15-1.57)	<.001	
Mucinous histology	57	1.22 (1.16-1.27)	<.001	20	1.51 (1.23-1.84)	<.001	
Signet ring histology	44	2.32 (2.08-2.57)	<.001	9	2.70 (1.77-4.14)	<.001	

Data presented as odds ratio (95% confidence interval).

CI, confidence interval; CIMP, CpG island methylator phenotype; MSI, microsatellite instability; OR, odds ratio.

^aIncludes studies that excluded individuals with Lynch syndrome, all hereditary syndromes, microsatellite instability, or family history of colorectal cancer.

N/A indicates not applicable.

Aldiab, 2017 30 Ye, 2015 11 Mueller, 2021 12 Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 38 Escobar, 2020, MSS tumors 14 King, 2021a 26 Secobar, 2020, MSS tumors 14 King, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 31 Chi, 2024 29 Ugal, 2023 14 Xicola, 2014 29 Ugal, 2023, MSS tumors 408 Holowatyl, 2023 765 Myer, 2022, African 166 Furuhashi, 2023 10 Chen, 2024 29 Jin, 2021 497 Ozer, 2021 203	67 80 788 50 35 988 42 29 94 35 241 39 38 1420 117 37 8 330 730 63 528 67 27 3171 1832 5669 373 1649 5729 1063 40	Events 43 244 59 173 45 83 28 226 126 99 66 665 16 7100 1758 54 62 302 567 631 87 521 7288 2016 11536 365 2143 8947 2091	Total 134 51 97 435 93 158 93 158 38 46 410 275 134 1462 1355 149 140 142 1340 1479 1237 16235 40 158 6931 4418 22932 1355 6629 20366	0.4% 0.7% 1.0% 0.8% 0.5% 0.5% 0.5% 0.9% 1.3% 0.8% 0.5% 0.8% 0.8% 1.7% 0.8% 1.1% 1.6% 3.3% 0.6% 0.5% 4.4% 4.6% 0.5% 4.8% 2.8%	M.H, Randorn, 95% C1 0.13 (0.05, 0.39) 4 0.35 (0.16, 0.74) 0.40 [0.22, 0.74] 0.43 (0.21, 0.86] 0.56 (0.25, 1.25) 0.57 (0.34, 0.96] 0.58 (0.22, 1.51] 0.59 (0.23, 1.52] 0.67 (0.35, 1.28] 0.68 [0.41, 1.14] 0.69 (0.32, 1.46] 0.70 (0.53, 0.93] 0.73 (0.29, 1.85] 0.76 (0.68, 0.85] 0.77 (0.50, 1.18] 0.78 (0.44, 1.40] 0.78 (0.51, 1.21] 0.79 (0.54, 1.98] 0.78 (0.54, 1.57] 0.78 (0.54, 1.42] 0.79 (0.56, 0.98] 0.81 (0.46, 1.42] 0.81 (0.47, 1.36] 0.82 (0.76, 0.89] 0.81 (0.46, 0.98] 0.82 (0.76, 0.89] 0.82 (0.76, 0.89] 0.84 (0.32, 2.20] 0.85 (0.76, 0.98] 0.84 (0.32, 2.20] 0.85 (0.76, 0.98] 0.89 (0.85, 0.98] 0.89 (0.85, 0.98] 0.99 (0.80, 1.00] 0.90 (0.85, 0.91] 0.90 (0.85, 0.91] 0.90 (0.85, 0.92] 0.90 (0.85, 0.12] 0.91 (0.86, 0.77) 0.90 (0.80, 1.17] 0.90 (0.80, 1.02] 0.91 (0.86, 0.97)	M.H, Random, 95% Cl
Raman, 2014 19 Aldiab, 2017 30 Ye, 2015 11 Mueller, 2021 12 Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kirm, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 220 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloiu, 2023 144 Xicola, 2014 7 Ugai, 2023 145 Myer, 2022, African 166 Furthashi, 2023 10 Chen, 2024 477 <tr< th=""><th>80 78 50 35 98 42 29 57 94 35 241 39 38 1420 117 37 78 330 730 63 3528 528 528 5729 3171 1832 5669 373 1649 5729 1063</th><th>24 59 173 28 26 26 106 105 105 105 105 105 105 105 105 105 105</th><th>51 97 4355 93 158 38 46 4100 275 134 1462 13550 629 1412 13650 1412 1340 1237 16235 400 158 6931 4418 22932 1355 6629</th><th>0.7% 1.0% 0.6% 1.3% 0.5% 0.5% 0.7% 2.7% 1.3% 0.8% 1.3% 0.8% 1.3% 0.8% 1.4% 3.3% 1.6% 3.4% 1.2% 0.6% 4.4% 0.8% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.4% 1.2% 1.2% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.5% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.3% 1.3% 1.2% 1.3%</th><th>$\begin{array}{c} 0.35 & [0.16, 0.74]\\ 0.40 & [0.22, 0.74]\\ 0.43 & [0.21, 0.86]\\ 0.56 & [0.25, 1.25]\\ 0.57 & [0.34, 0.96]\\ 0.58 & [0.22, 1.51]\\ 0.59 & [0.23, 1.52]\\ 0.67 & [0.35, 1.28]\\ 0.68 & [0.41, 1.14]\\ 0.69 & [0.32, 1.46]\\ 0.70 & [0.53, 0.93]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.38, 1.57]\\ 0.78 & [0.38, 1.57]\\ 0.78 & [0.38, 1.57]\\ 0.78 & [0.44, 1.40]\\ 0.79 & [0.64, 0.98]\\ 0.80 & [0.67, 1.18]\\ 0.80 & [0.67, 1.21]\\ 0.78 & [0.38, 1.57]\\ 0.80 & [0.68, 0.85]\\ 0.81 & [0.44, 1.40]\\ 0.78 & [0.38, 1.57]\\ 0.80 & [0.65, 0.98]\\ 0.81 & [0.46, 1.42]\\ 0.81 & [0.37, 1.78]\\ 0.84 & [0.36, 0.98]\\ 0.84 & [0.36, 0.100]\\ 0.90 & [0.86, 0.98]\\ 0.90 & [0.80, 0.100]\\ 0.90 &$</th><th></th></tr<>	80 78 50 35 98 42 29 57 94 35 241 39 38 1420 117 37 78 330 730 63 3528 528 528 5729 3171 1832 5669 373 1649 5729 1063	24 59 173 28 26 26 106 105 105 105 105 105 105 105 105 105 105	51 97 4355 93 158 38 46 4100 275 134 1462 13550 629 1412 13650 1412 1340 1237 16235 400 158 6931 4418 22932 1355 6629	0.7% 1.0% 0.6% 1.3% 0.5% 0.5% 0.7% 2.7% 1.3% 0.8% 1.3% 0.8% 1.3% 0.8% 1.4% 3.3% 1.6% 3.4% 1.2% 0.6% 4.4% 0.8% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.4% 1.2% 1.2% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.2% 1.2% 1.4% 1.5% 1.4% 1.5% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.4% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.2% 1.3% 1.3% 1.3% 1.2% 1.3%	$\begin{array}{c} 0.35 & [0.16, 0.74]\\ 0.40 & [0.22, 0.74]\\ 0.43 & [0.21, 0.86]\\ 0.56 & [0.25, 1.25]\\ 0.57 & [0.34, 0.96]\\ 0.58 & [0.22, 1.51]\\ 0.59 & [0.23, 1.52]\\ 0.67 & [0.35, 1.28]\\ 0.68 & [0.41, 1.14]\\ 0.69 & [0.32, 1.46]\\ 0.70 & [0.53, 0.93]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.38, 1.57]\\ 0.78 & [0.38, 1.57]\\ 0.78 & [0.38, 1.57]\\ 0.78 & [0.44, 1.40]\\ 0.79 & [0.64, 0.98]\\ 0.80 & [0.67, 1.18]\\ 0.80 & [0.67, 1.21]\\ 0.78 & [0.38, 1.57]\\ 0.80 & [0.68, 0.85]\\ 0.81 & [0.44, 1.40]\\ 0.78 & [0.38, 1.57]\\ 0.80 & [0.65, 0.98]\\ 0.81 & [0.46, 1.42]\\ 0.81 & [0.37, 1.78]\\ 0.84 & [0.37, 1.78]\\ 0.84 & [0.37, 1.78]\\ 0.84 & [0.37, 1.78]\\ 0.84 & [0.37, 1.78]\\ 0.84 & [0.37, 1.78]\\ 0.84 & [0.36, 0.98]\\ 0.84 & [0.36, 0.100]\\ 0.90 & [0.86, 0.98]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & [0.80, 0.100]\\ 0.90 & $	
Aldiab, 2017 30 Ye, 2015 11 Mueller, 2021 12 Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 38 Escobar, 2020, MSS tumors 14 King, 2021a 26 Escobar, 2020, MSS tumors 14 King, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 29 Ugai, 2023 14 Xicola, 2012 10 Gao, 2022 1222 Emiloju, 2023 14 Xicola, 2014 29 Myer, 2022, African 408 Holowatyl, 2023 765 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2024 <td< td=""><td>78 50 355 98 42 299 57 94 35 241 39 38 1420 117 37 78 330 730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063</td><td>59 173 465 83 225 126 866 105 105 105 105 105 105 105 105 105 105</td><td>97 435 93 158 38 46 410 275 134 1462 1340 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629</td><td>$\begin{array}{c} 1.0\%\\ 0.8\%\\ 0.5\%\\ 0.5\%\\ 0.9\%\\ 1.3\%\\ 0.7\%\\ 2.7\%\\ 0.8\%\\ 1.7\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 0.6\%\\ 4.4\%\\ 1.8\%\\ 2.8\%\\ 4.8\%\\ 2.8\%\\ 2.8\%\end{array}$</td><td>$\begin{array}{c} 0.40 \ [0.22, 0.74]\\ 0.43 \ [0.21, 0.86]\\ 0.56 \ [0.22, 1.25]\\ 0.57 \ [0.34, 0.96]\\ 0.58 \ [0.22, 1.51]\\ 0.59 \ [0.22, 1.51]\\ 0.59 \ [0.22, 1.51]\\ 0.69 \ [0.41, 1.4]\\ 0.59 \ [0.32, 1.46]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.77 \ [0.50, 1.18]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.44, 1.40]\\ 0.79 \ [0.64, 0.98]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.46, 0.98]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.32, 2.20]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.89 \ [0.80, 1.00]\\ 0.99 \ [0.80, 1.00]\\ 0.99 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.9$</td><td></td></td<>	78 50 355 98 42 299 57 94 35 241 39 38 1420 117 37 78 330 730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063	59 173 465 83 225 126 866 105 105 105 105 105 105 105 105 105 105	97 435 93 158 38 46 410 275 134 1462 1340 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	$\begin{array}{c} 1.0\%\\ 0.8\%\\ 0.5\%\\ 0.5\%\\ 0.9\%\\ 1.3\%\\ 0.7\%\\ 2.7\%\\ 0.8\%\\ 1.7\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 1.6\%\\ 0.6\%\\ 4.4\%\\ 1.8\%\\ 2.8\%\\ 4.8\%\\ 2.8\%\\ 2.8\%\end{array}$	$\begin{array}{c} 0.40 \ [0.22, 0.74]\\ 0.43 \ [0.21, 0.86]\\ 0.56 \ [0.22, 1.25]\\ 0.57 \ [0.34, 0.96]\\ 0.58 \ [0.22, 1.51]\\ 0.59 \ [0.22, 1.51]\\ 0.59 \ [0.22, 1.51]\\ 0.69 \ [0.41, 1.4]\\ 0.59 \ [0.32, 1.46]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.77 \ [0.50, 1.18]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.44, 1.40]\\ 0.79 \ [0.64, 0.98]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.46, 0.98]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.32, 2.20]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.89 \ [0.80, 1.00]\\ 0.99 \ [0.80, 1.00]\\ 0.99 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.9$	
Ye, 2015 11 Mueiler, 2021 12 Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kim, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Ugai, 2022 10 Gao, 2022 102 Gao, 2022 102 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 164 Furpes-Sharf, 2022 33 Myer, 2022, Karican 616 <	50 35 98 42 29 67 94 35 241 39 38 1420 117 37 38 330 730 63 3528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	173 45 83 28 26 126 66 65 105 105 105 105 105 105 105 105 105 10	435 93 158 38 46 10275 134 1462 1421 385 149 110 626 1412 1340 179 1237 16235 400 158 6931 4418 22932 1355 6629	0.8% 0.6% 1.3% 0.5% 0.9% 1.3% 0.7% 0.8% 1.7% 0.8% 1.7% 0.8% 1.1% 1.6% 3.3% 1.2% 3.4% 1.2% 0.6% 4.6% 0.5% 4.2% 4.8% 2.8% 2.7%	$\begin{array}{c} 0.43 \begin{array}{[} [0.21, 0.86]\\ 0.56 \begin{array}{[} [0.25, 1.26]\\ 0.57 \begin{array}{[} [0.33, 4.096]\\ 0.57 \begin{array}{[} [0.33, 4.096]\\ 0.57 \begin{array}{[} [0.32, 1.52]\\ 0.57 \begin{array}{[} [0.32, 1.52]\\ 0.67 \begin{array}{[} [0.32, 1.52]\\ 0.67 \begin{array}{[} [0.32, 1.52]\\ 0.67 \begin{array}{[} [0.32, 1.52]\\ 0.73 \begin{array}{[} [0.32, 1.46]\\ 0.70 \begin{array}{[} [0.32, 1.46]\\ 0.77 \begin{array}{[} [0.32, 1.45]\\ 0.73 \begin{array}{[} [0.32, 1.45]\\ 0.77 \begin{array}{[} [0.50, 1.18]\\ 0.77 \begin{array}{[} [0.50, 1.18]\\ 0.78 \begin{array}{[} [0.54, 1.21]\\ 0.78 \begin{array}{[} [0.64, 0.98]\\ 0.80 \begin{array}{[} [0.44, 1.40]\\ 0.78 \begin{array}{[} [0.64, 0.98]\\ 0.80 \begin{array}{[} [0.44, 1.40]\\ 0.80 \begin{array}{[} [0.44, 1.36]\\ 0.80 \begin{array}{[} [0.44, 1.36]\\ 0.80 \begin{array}{[} [0.44, 1.36]\\ 0.80 \begin{array}{[} [0.42, 1.21]\\ 0.91 \begin{array}{[} [0.32, 1.22]\\ 0.81 \begin{array}{[} [0.37, 1.78]\\ 0.82 \begin{array}{[} [0.34, 2.10]\\ 0.84 \begin{array}{[} [0.32, 2.20]\\ 0.86 \begin{array}{[} [0.34, 2.10]\\ 0.86 \begin{array}{[} [0.34, 2.10]\\ 0.80 \begin{array}{[} [0.34, 2.10]\\ 0.86 \begin{array}{[} [0.34, 2.10]\\ 0.86 \begin{array}{[} [0.36, 0.86]\\ 0.80 \begin{array}{[} [0.36, 0.86$	
Mueller, 2021 12 Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kim, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Leu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 220 Ugai, 2022 10 Gao, 2022 1272 Emilolu, 2023 144 Xicola, 2014 77 Ugai, 2022 10 Gao, 2022, European 2697 Lipsyc-Sharf, 2022 33 Jin, 2021 407 Ver, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 12 Yazabi, 2023 10	36 98 42 29 57 94 35 2411 39 38 1420 117 37 330 63 330 63 3528 67 27 3171 1832 5669 373 1649 5729 1063 40	46 83 28 26 126 99 66 66 65 105 105 170 170 158 64 62 302 567 631 87 631 87 631 87 621 377 2553 2016 11636 2143 365 2143 38947	93 168 38 46 410 275 134 1462 1355 401 626 1412 1340 626 1412 1340 1237 16235 401 158 6931 4418 22932 1355 6629	$\begin{array}{c} 0.6\% \\ 1.3\% \\ 0.5\% \\ 0.5\% \\ 0.9\% \\ 0.7\% \\ 2.7\% \\ 0.8\% \\ 0.6\% \\ 4.4\% \\ 1.7\% \\ 0.8\% \\ 1.1\% \\ 1.6\% \\ 3.3\% \\ 4.6\% \\ 0.5\% \\ 4.6\% \\ 0.5\% \\ 4.2\% \\ 4.8\% \\ 2.8\% \\ 2.8\% \\ 2.8\% \\ 3.3\% \end{array}$	$\begin{array}{c} 0.56 \ [0.25, 1.25]\\ 0.57 \ [0.34, 0.96]\\ 0.58 \ [0.22, 1, 51]\\ 0.59 \ [0.23, 1.52]\\ 0.68 \ [0.41, 1.14]\\ 0.68 \ [0.35, 1.28]\\ 0.70 \ [0.53, 0.93]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.68, 0.85]\\ 0.77 \ [0.50, 1.16]\\ 0.76 \ [0.38, 0.86]\\ 0.77 \ [0.50, 1.16]\\ 0.78 \ [0.34, 1.40]\\ 0.78 \ [0.34, 1.57]\\ 0.78 \ [0.34, 1.57]\\ 0.78 \ [0.44, 1.40]\\ 0.79 \ [0.64, 0.98]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.89 \ [0.80, 1.00]\\ 0.90 \ [0.80, 0.10]\\ 0.90 \ [0.80, 0.100]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ $	
Arriba, 2019 38 Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 King, 2021a 26 Scobar, 2020, MSS tumors 14 King, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 31 Chi, 2024 29 Ugai, 2023 14 Xicola, 2014 29 Ugai, 2023 14 Yold, 2023 14 Holowatyl, 2023 10 Gao, 2022 1272 Emiloju, 2023 14 Holowatyl, 2023 16 Holowatyl, 2023 16 Furthashi, 2023 10 Chen, 2024 29	98 42 29 57 94 35 241 39 38 1420 117 37 78 330 730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	83 26 26 126 865 105 105 105 105 105 16 105 16 302 567 831 87 631 87 631 7288 21 37 2553 2016 11536 2143 8947	158 38 46 410 275 134 365 1462 1462 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	$\begin{array}{c} 1.3\%\\ 0.5\%\\ 0.9\%\\ 1.3\%\\ 2.7\%\\ 0.8\%\\ 4.4\%\\ 1.7\%\\ 1.6\%\\ 1.1\%\\ 1.6\%\\ 1.2\%\\ 3.3\%\\ 1.2\%\\ 0.6\%\\ 4.6\%\\ 0.5\%\\ 4.2\%\\ 4.8\%\\ 2.8\%\\ 2.8\%\\ 2.3\%\end{array}$	$\begin{array}{c} 0.57 & [0.34, 0.96]\\ 0.58 & [0.22, 1, 51]\\ 0.59 & [0.22, 1, 52]\\ 0.67 & [0.35, 1, 28]\\ 0.68 & [0.41, 1, 14]\\ 0.59 & [0.32, 1, 46]\\ 0.73 & [0.36, 1, 45]\\ 0.73 & [0.36, 1, 45]\\ 0.73 & [0.36, 1, 45]\\ 0.73 & [0.36, 1, 45]\\ 0.76 & [0.68, 0.86]\\ 0.77 & [0.50, 1, 18]\\ 0.78 & [0.34, 1, 57]\\ 0.78 & [0.44, 1, 40]\\ 0.78 & [0.51, 1, 21]\\ 0.79 & [0.64, 0.98]\\ 0.80 & [0.47, 1, 36]\\ 0.80 & [0.65, 0, 98]\\ 0.81 & [0.37, 1, 78]\\ 0.64 & [0.38, 1, 57]\\ 0.76 & [0.68, 0.89]\\ 0.81 & [0.37, 1, 78]\\ 0.64 & [0.32, 2, 20]\\ 0.85 & [0.34, 2, 10]\\ 0.86 & [0.76, 0, 89]\\ 0.89 & [0.80, 1, 00]\\ 0.89 & [0.80, 1, 00]\\ 0.99 & [0.80, 1, 00]\\ 0.99 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 17]\\ 0.90 & [0.80, 1, 02]\\ 0.91 & [0.80, 1, 02$	
Laskar, 2015 26 Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kim, 2021 89 Alharbi, 2021 18 Kinz, 2014 18 Kirzin, 2014 18 Kirzin, 2014 18 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloiu, 2023 14 Xicola, 2014 7 Ugai, 2022, MSS tumors 408 Holowaty, 2023 765 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2024 427 Jip.2021 437 Kota, 2023 10 Cheng, 2023 108	42 29 67 94 35 241 17 37 37 38 330 730 63 528 67 27 3171 1832 5669 373 1649 5729 1063	28 26 126 66 665 105 16 7100 170 158 64 62 302 567 631 7288 21 7288 21 37 2553 2113 37 2553 21136 2153 2153 2553 2143 365 2143 38947	38 46 410 275 134 1462 366 13550 421 385 149 110 626 1412 1340 179 1237 16235 400 158 6931 4418 22932 1355 6629	$\begin{array}{c} 0.5\%\\ 0.5\%\\ 0.9\%\\ 1.3\%\\ 0.7\%\\ 0.8\%\\ 0.5\%\\ 1.7\%\\ 0.8\%\\ 1.7\%\\ 1.6\%\\ 3.3\%\\ 1.1\%\\ 1.6\%\\ 3.4\%\\ 1.2\%\\ 3.4\%\\ 1.6\%\\ 0.5\%\\ 4.6\%\\ 0.5\%\\ 4.2\%\\ 4.8\%\\ 2.8\%\\ 2.8\%\end{array}$	$\begin{array}{c} 0.56 \\ [0.22, 1.51] \\ 0.59 \\ [0.23, 1.52] \\ 0.67 \\ [0.35, 1.28] \\ 0.68 \\ [0.41, 1.14] \\ 0.69 \\ [0.32, 1.46] \\ 0.73 \\ [0.32, 1.46] \\ 0.73 \\ [0.32, 1.45] \\ 0.73 \\ [0.32, 1.45] \\ 0.76 \\ [0.58, 0.88] \\ 0.77 \\ [0.50, 1.18] \\ 0.76 \\ [0.58, 0.88] \\ 1.57 \\ [0.58, 0.54] \\ 0.78 \\ [0.51, 1.21] \\ 0.78 \\ [0.44, 1.40] \\ 0.78 \\ [0.51, 1.21] \\ 0.78 \\ [0.64, 0.98] \\ 0.80 \\ [0.47, 1.36] \\ 0.80 \\ [0.47, 1.36] \\ 0.80 \\ [0.46, 1.42] \\ 0.81 \\ [0.37, 1.78] \\ 0.82 \\ [0.37, 1.78] \\ 0.82 \\ [0.34, 2.10] \\ 0.86 \\ [0.76, 0.98] \\ 0.84 \\ 2.10] \\ 0.86 \\ [0.76, 0.98] \\ 0.89 \\ 0.80 \\ 1.02 \\ 2.22 \\ 0.85 \\ 0.98 \\ 0.80 \\ 1.00 \\ 0.90 \\ 0.80 \\ 0.95 \\ 0.95 \\ 0.90 \\ 0.89 \\ 0.95 \\ 0.90 \\ 0.89 \\ 0.95 \\ 0.90 \\ 0.89 \\ 0.91 \\ 1.71 \\ 0.90 \\ 0.80 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 \\ 0.90 \\ 1.17 $	
Wang, 2021a 12 Chouhan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kim, 2021 89 Aharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Leu, 2019 84 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 10 Gao, 2022 10 Gao, 2023 144 Xicola, 2014 7 Ugai, 2023 144 Xicola, 2014 7 Ugai, 2023 144 Xicola, 2014 7 Ugai, 2023 144 Xicola, 2014 7 Quer, 2022, European 2687 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 10	29 57 94 35 241 39 38 1420 117 37 330 63 3528 67 27 3171 1832 5669 373 1649 5729 1063 40	25 126 99 66 605 105 105 105 16 7100 170 158 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	46 410 2755 134 1462 1944 36 13550 421 385 149 110 626 1412 1340 179 1237 1625 40 158 6931 4418 22932 1355 6629	0.5% 0.9% 1.3% 0.7% 2.7% 0.5% 4.4% 1.7% 0.8% 1.1% 1.8% 1.2% 3.3% 1.1% 0.8% 4.6% 0.5% 0.5% 0.5% 4.4% 4.8% 2.8%	$\begin{array}{c} 0.59 \ [0.23, 1.52]\\ 0.67 \ [0.35, 1.28]\\ 0.68 \ [0.41, 1.14]\\ 0.69 \ [0.32, 1.46]\\ 0.70 \ [0.53, 0.93]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.29, 1.85]\\ 0.76 \ [0.68, 0.85]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.18]\\ 0.78 \ [0.38, 1.57]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.44, 1.40]\\ 0.79 \ [0.64, 0.86]\\ 0.80 \ [0.65, 0.98]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.76]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.37, 1.76]\\ 0.85 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.89 \ [0.80, 1.00]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.10]\\ 0.90 \ [0.80, 0.1, 00]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 \ [0.80, 0.80]\\ 0.90 $	
Chouñan, 2019 13 Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kim, 2021 89 Alharbi, 2021 18 Kitzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 29 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 765 Myer, 2022, European 2697 Lipsvc-Shart, 2022 93 Jin, 2021 497 Orer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 12 Ya Zaabi, 2023 10 Chen, 2023 17 Meng, 2023	57 94 35 241 39 38 1420 117 37 78 330 730 63 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	126 99 66 665 105 170 170 170 62 302 567 631 87 251 7288 211 7288 211 37 2553 2016 11536 2143 365	410 275 134 4 1462 194 365 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	0.9% 1.3% 0.7% 0.8% 0.5% 4.4% 1.7% 0.8% 1.6% 3.3% 1.6% 3.4% 1.1% 0.6% 0.5% 0.5% 4.2% 4.4% 4.8% 2.8%	$\begin{array}{c} 0.67 \begin{array}{[} 0.36 \\ 10.36 \\ 10.41 \\ 1.14 \\ 0.69 \\ 10.22 \\ 1.45 \\ 0.73 \\ 10.36 \\ 1.45 \\ 0.73 \\ 10.36 \\ 1.45 \\ 0.73 \\ 10.36 \\ 1.45 \\ 0.73 \\ 10.36 \\ 1.45 \\ 0.77 \\ 10.50 \\ 1.18 \\ 0.76 \\ 10.48 \\ 1.57 \\ 10.50 \\ 1.18 \\ 0.78 \\ 10.48 \\ 1.57 \\ 1.57 \\ 1.58 \\ 1.57 \\ 1.$	
Khan, 2016 26 Escobar, 2020, MSS tumors 14 Kirm, 2021 89 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 10 Gao, 2023, MSS tumors 408 Holowath, 2023 765 Myer, 2022, European 2697 Lipsyc-Shart, 2022 93 Jin, 2021 497 Ver, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 92 Pereira, 2020 108 Araujo, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 10	94 35 2411 39 38 1420 117 37 78 330 63 528 67 27 3171 1832 5669 373 1649 5729 1063 40	99 66 665 105 16 7100 170 158 64 62 302 567 631 7288 21 37 2553 213 37 2553 2143 365 2143 8947	275 134 1462 194 36 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	$\begin{array}{c} 1.3\%\\ 0.7\%\\ 2.7\%\\ 0.8\%\\ 0.5\%\\ 4.4\%\\ 1.7\%\\ 0.8\%\\ 1.6\%\\ 3.3\%\\ 1.2\%\\ 0.6\%\\ 4.6\%\\ 0.5\%\\ 4.8\%\\ 2.8\%\\ 2.8\%\\ 4.3\%\end{array}$	$\begin{array}{c} 0.68 \begin{array}{[} [0.41 \\ .0.69 \\ [0.32 \\ .0.53 \\ .0.73 \\ [0.36 \\ .0.73 \\ [0.36 \\ .0.73 \\ [0.36 \\ .0.75 \\ .0.75 \\ [0.36 \\ .0.77 \\ [0.50 \\ .0.77 \\ [0.50 \\ .0.77 \\ [0.50 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.77 \\ [0.50 \\ .0.88 \\ .0.81 \\ [0.37 \\ .0.78 \\ .0.81 \\ [0.37 \\ .0.78 \\ .0.81 \\ [0.37 \\ .0.78 \\ .0.81 \\ [0.37 \\ .0.78 \\ .0.81 \\ .0.81 \\ .0.37 \\ .0.81 \\ .0.32 \\ .0.81 \\ [0.37 \\ .0.78 \\ .0.81 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81 \\ .0.32 \\ .0.81$	
Escobar, 2020, MSS tumors 14 Kim, 2021 89 Aharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 202a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 29 Ugai, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holewahj, 2023 785 Myer, 2022, European 2697 Lipsv-Shart, 2022 933 Jin, 2021 497 Ozer, 2021 2381 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2024 10 Alzaabi, 2023 17 Meng, 2023 10 Chen, 2024 10 Alzaabi, 2023 17 Meng, 2023 17<	35 241 38 1420 117 37 78 330 730 730 730 730 730 730 730 730 730	66 665 105 7100 1700 158 64 62 302 567 631 87 521 7288 37 521 37 2553 2016 11536 2143 365 2143	134 1462 194 366 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	0.7% 2.7% 0.8% 4.4% 1.7% 1.6% 3.3% 1.1% 0.6% 0.5% 0.5% 0.5% 0.5% 4.4% 4.8% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.69 \ [0.32, 1.46]\\ 0.70 \ [0.53, 0.93]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.29, 1.85]\\ 0.76 \ [0.68, 0.85]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.121]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.51, 1.21]\\ 0.79 \ [0.64, 0.96]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.76]\\ 0.81 \ [0.37, 1.76]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.96 \ [0.80, 0.80]\\ 0.96 \ [0.36, 0.96]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.100]\\ 0.90 \ [0.80, 0.1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]$	
Kim, 2021 98 Alharbi, 2021 18 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Och, 2024 29 Ugai, 2023 14 Xicola, 2014 79 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2697 Lipsvc-Sharf, 2022 933 Jin, 2021 497 Ozer, 2021 203 Myer, 2022, African 616 Furuhashi, 2023 10 Cheng, 2023 12 Ya Zsabi, 2023 17 Meng, 2023 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC <t <="" td=""><td>241 39 38 1420 117 37 78 330 730 63 67 27 3171 29 34 1832 5669 373 1649 5729 1063 40</td><td>865 105 16 7100 170 54 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947</td><td>1462 194 36 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629</td><td>2.7% 0.8% 4.4% 1.7% 0.8% 1.6% 3.3% 1.2% 3.4% 0.6% 4.6% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%</td><td>$\begin{array}{c} 0.69 \ [0.32, 1.46]\\ 0.70 \ [0.53, 0.93]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.29, 1.85]\\ 0.76 \ [0.68, 0.85]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.121]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.51, 1.21]\\ 0.79 \ [0.64, 0.96]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.76]\\ 0.81 \ [0.37, 1.76]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.96 \ [0.80, 0.80]\\ 0.96 \ [0.36, 0.96]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.100]\\ 0.90 \ [0.80, 0.1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]$</td><td></td></t>	241 39 38 1420 117 37 78 330 730 63 67 27 3171 29 34 1832 5669 373 1649 5729 1063 40	865 105 16 7100 170 54 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	1462 194 36 13550 421 385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	2.7% 0.8% 4.4% 1.7% 0.8% 1.6% 3.3% 1.2% 3.4% 0.6% 4.6% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.69 \ [0.32, 1.46]\\ 0.70 \ [0.53, 0.93]\\ 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.29, 1.85]\\ 0.76 \ [0.68, 0.85]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.18]\\ 0.77 \ [0.50, 1.121]\\ 0.78 \ [0.44, 1.40]\\ 0.78 \ [0.51, 1.21]\\ 0.79 \ [0.64, 0.96]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.76]\\ 0.81 \ [0.37, 1.76]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.34, 2.10]\\ 0.85 \ [0.34, 2.10]\\ 0.96 \ [0.80, 0.80]\\ 0.96 \ [0.36, 0.96]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.80]\\ 0.99 \ [0.80, 0.100]\\ 0.90 \ [0.80, 0.1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.07]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]$	
Kim, 2021 98 Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 79 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2697 Lipsvc-Shart, 2022 933 Jin, 2021 497 Ozer, 2021 108 Araujo, 2023 17 Merg, 2023 108 Araujo, 2021 498 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 166	39 38 1420 117 37 78 330 730 63 528 67 27 3171 121 1832 5669 373 1649 5729 1063 40	105 16 7100 170 158 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 38947	194 36 13550 421 385 149 120 626 1412 1340 149 1237 16235 40 158 6931 4418 22932 1355 6629	0.8% 0.5% 4.4% 0.8% 1.7% 0.8% 1.1% 1.2% 3.3% 1.2% 3.4% 0.6% 4.6% 0.5% 0.5% 0.5% 0.5% 4.2% 4.4% 4.8% 2.8% 2.8%	$\begin{array}{c} 0.70 & [0.53, 0.93]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.36, 1.45]\\ 0.73 & [0.38, 1.57]\\ 0.76 & [0.68, 0.85]\\ 0.77 & [0.50, 1.18]\\ 0.78 & [0.38, 1.57]\\ 0.78 & [0.44, 1.40]\\ 0.78 & [0.51, 1.21]\\ 0.79 & [0.64, 0.98]\\ 0.80 & [0.47, 1.36]\\ 0.80 & [0.46, 1.42]\\ 0.81 & [0.37, 1.78]\\ 0.82 & [0.76, 0.89]\\ 0.84 & [0.32, 2.20]\\ 0.85 & [0.34, 2.10]\\ 0.86 & [0.76, 0.98]\\ 0.89 & [0.80, 1.02]\\ 0.89 & [0.80, 1.02]\\ 0.89 & [0.80, 1.02]\\ 0.99 & [0.80, 1.02]\\ 0.99 & [0.80, 1.17]\\ 0.90 & [0.80, 1.17]\\ 0.$	
Alharbi, 2021 18 Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloiu, 2023 144 Xicola, 2014 7 Ugai, 2022, MSS tumors 408 Holowath, 2023 765 Myer, 7022, European 2697 Lipsyc-Shart, 2022 93 Jin, 2021 497 Ver, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 92 Pereira, 2020 108 Araujo, 2021 497 Milauer, 2019, MDACC 313 Aljehani, 2023 10	39 38 1420 117 37 78 330 730 63 528 67 27 3171 121 1832 5669 373 1649 5729 1063 40	105 16 7100 170 158 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 38947	194 36 13550 421 385 149 120 626 1412 1340 149 1237 16235 40 158 6931 4418 22932 1355 6629	0.8% 0.5% 4.4% 0.8% 1.7% 0.8% 1.1% 1.2% 3.3% 1.2% 3.4% 0.6% 4.6% 0.5% 0.5% 0.5% 0.5% 4.2% 4.4% 4.8% 2.8% 2.8%	$\begin{array}{c} 0.73 \ [0.36, 1.45]\\ 0.73 \ [0.29, 1.86]\\ 0.77 \ [0.50, 1.18]\\ 0.76 \ [0.38, 0.85]\\ 0.77 \ [0.50, 1.18]\\ 0.78 \ [0.51, 1.21]\\ 0.78 \ [0.51, 1.21]\\ 0.79 \ [0.64, 0.98]\\ 0.80 \ [0.67, 1.36]\\ 0.80 \ [0.67, 0.98]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.32, 2.20]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.80 \ [0.85, 0.95]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.17]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.90 \ [0.80, 1.02]\\ 0.91 \ [0.80, 1.02]\\ 0.$	
Kirzin, 2014, MSS tumors 14 Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 29 Ugai, 2023 10 Gao, 2022 1272 Emiloiju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holewahj, 2023 785 Myer, 2022, European 2697 Lipsvs-Shart, 2022 933 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Jiehani, 2023	38 1420 117 37 78 330 730 63 528 67 27 3171 129 34 1221 1832 5669 373 1649 5729 1063 40	16 7100 170 54 62 302 567 631 87 631 7288 21 37 2553 2016 11536 11536 365 2143 8947	36 13550 421 385 149 110 626 1412 1340 179 1237 16235 400 158 6931 4418 22932 1355 6629	0.5% 4.4% 1.7% 0.8% 1.1% 1.6% 3.3% 1.2% 4.6% 0.6% 4.6% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.73 \ [0.29, 1.85]\\ 0.76 \ [0.86, 0.86]\\ 0.77 \ [0.38, 1.57]\\ 0.78 \ [0.34, 1.40]\\ 0.78 \ [0.34, 1.40]\\ 0.78 \ [0.51, 1.21]\\ 0.79 \ [0.64, 0.98]\\ 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.65, 0.98]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.32, 2.20]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.90 \ [0.85, 0.95]\\ 0.90 \ [0.89, 1.17]\\ 0.90 \ [0.80, 1.17]\\ 0.$	
Lieu, 2019 648 Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holewatyi, 2023 785 Myer, 2022, European 2697 Lipsvc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2023 10 Cheng, 2023 10 Cheng, 2023 10 Cheng, 2023 10 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 106	1420 117 37 78 330 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	7100 170 158 54 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	13550 421 385 149 110 626 1412 1340 179 1237 16237 40 158 6931 4418 22932 1355 6629	4.4% 1.7% 0.8% 1.6% 3.3% 1.2% 4.6% 0.5% 4.6% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.76 \\ \hline 0.68 \\ 0.85 \\ 0.77 \\ [0.50, 1.18 \\ 0.78 \\ [0.38, 1.57 \\ 0.78 \\ [0.44, 1.40 \\ 0.78 \\ [0.64, 0.98 \\ 0.80 \\ [0.64, 0.98 \\ 0.80 \\ [0.65, 1.36 \\ 0.81 \\ 0.37 \\ 1.78 \\ 0.82 \\ [0.76, 0.89 \\ 0.84 \\ [0.37, 1.78 \\ 0.82 \\ 0.76 \\ 0.89 \\ 0.84 \\ [0.32, 2.20 \\ 0.85 \\ 0.34 \\ 2.10 \\ 0.86 \\ [0.76, 0.98 \\ 0.89 \\ 0.89 \\ 0.80 \\ 0.80 \\ 0.89 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ 0.80 \\ 0.177 \\ 0.90 \\ 0.80 \\ $	
Foppa, 2022a 40 Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ch, 2024 29 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 144 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowaty, 2023 785 Myer, 2022, European 2697 Lipsyc-Sharf, 2022 93 Jin, 2021 497 Ver, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zsabi, 2023 10 Araujo, 2021 498 Du, 2023 10 Araujo, 2021 498 Juenal, 2023 10 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 164	117 37 78 3300 730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	170 158 54 62 302 567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	421 385 149 110 626 1412 1340 179 16235 40 158 6931 4418 22932 1355 6629	$\begin{array}{c} 1.7\% \\ 0.8\% \\ 1.1\% \\ 1.6\% \\ 3.3\% \\ 1.2\% \\ 3.4\% \\ 1.1\% \\ 0.6\% \\ 4.6\% \\ 0.5\% \\ 4.2\% \\ 4.4\% \\ 4.8\% \\ 4.8\% \\ 4.3\% \end{array}$	$\begin{array}{c} 0.77 & [0.50] & 1.18]\\ 0.78 & [0.38] & 1.57]\\ 0.78 & [0.44] & 1.40]\\ 0.78 & [0.51] & 1.21]\\ 0.79 & [0.64] & 0.98]\\ 0.80 & [0.65] & 0.98]\\ 0.81 & [0.46] & 1.42]\\ 0.81 & [0.46] & 1.42]\\ 0.81 & [0.37] & 1.78]\\ 0.82 & [0.76] & 0.89]\\ 0.84 & [0.37] & 1.78]\\ 0.85 & [0.34] & 2.10]\\ 0.86 & [0.76] & 0.98]\\ 0.89 & [0.80] & 1.00]\\ 0.90 & [0.80] & 1.01]\\ 0.90 & [0.80] & 1.17]\\ 0.90 & [0.80] & 1.07]\\ \end{array}$	
Martinez-Perez, 2023 13 Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ch, 2024 29 Ugai, 2022 10 Gao, 2022 12727 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowabi, 2023 785 Myer, 2022, European 2697 Lipsv-Shart, 2022 933 Jin, 2021 497 Ozer, 2021 231 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	37 78 330 7300 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 5729 1063 40	158 54 62 302 567 631 87 521 7288 211 37 2553 2016 11536 365 2143 8947	385 149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	0.8% 1.1% 1.6% 3.3% 1.2% 4.6% 0.5% 4.6% 0.5% 4.2% 4.8% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.79 & [0.38] & 1.57] \\ 0.78 & [0.44, 1.40] \\ 0.78 & [0.51, 1.21] \\ 0.79 & [0.64, 0.98] \\ 0.80 & [0.47, 1.36] \\ 0.80 & [0.46, 1.42] \\ 0.81 & [0.37, 1.78] \\ 0.82 & [0.76, 0.89] \\ 0.84 & [0.32, 2.20] \\ 0.85 & [0.34, 2.10] \\ 0.86 & [0.76, 0.98] \\ 0.89 & [0.80, 1.00] \\ 0.90 & [0.89, 1.07] \\ 0.90 & [0.89, 1.17] \\ 0.90 & [0.89, 1.17] \\ 0.90 & [0.80, 1.07] \\ 0.90 & [0.80, 1.17] \\ 0.90 & [0.80, 1.07] \\ 0.91 & [0.80, 1.17] \\ 0.90 & [0.80, 1.07] \\ 0.91 & [0.80, 1.17] \\ 0.90 & [0.80, 1.17] \\ 0.90 & [0.80, 1.17] \\ 0.90 & [0.80, 1.02] \\ \end{array}$	
Rho, 2017 24 Xu, 2020 166 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Chang, 2017 22 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2697 Lipsvc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2023 10 Chen, 2024 427 Al Zaabi, 2023 10 Chen, 2023 12 Yal Zaabi, 2023 10 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	78 330 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	54 62 302 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	149 110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	1.1% 1.6% 3.3% 1.2% 3.4% 0.6% 4.6% 0.5% 4.2% 4.8% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.78 \\ [0.44, 1, 40] \\ 0.78 \\ [0.51, 1, 21] \\ 0.79 \\ [0.64, 0, 98] \\ 0.80 \\ [0.47, 1, 36] \\ 0.80 \\ [0.46, 1, 42] \\ 0.81 \\ [0.37, 1, 78] \\ 0.82 \\ [0.76, 0, 89] \\ 0.84 \\ [0.32, 2, 20] \\ 0.85 \\ [0.34, 2, 10] \\ 0.86 \\ [0.76, 0, 98] \\ 0.89 \\ [0.80, 1, 00] \\ 0.99 \\ [0.80, 1, 00] \\ 0.99 \\ [0.80, 1, 10] \\ 0.90 \\ 0.90 \\ 0.9$	
Xu, 2020 166 Cercek, 2021 310 Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 29 Ugal, 2022 10 Gao, 2022 1272 Emiloiu, 2023 14 Xicola, 2014 7 Ugai, 2023, MS5 turnors 408 Holowahi, 2023 765 Myer, 2022, European 2697 Jin, 2021 497 Ozer, 2021 203 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 127 Mag, 2023 10 Araujo, 2021 497 Alzabu, 2023 10 Paraujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	330 730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	62 302 567 631 7288 21 37 2553 2016 11536 365 2143 8947	110 626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	1.6% 3.3% 1.2% 3.4% 1.1% 0.6% 4.6% 0.5% 4.6% 4.2% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.78 \\ [0.51] \\ 1.21 \\ 0.79 \\ [0.64] \\ 0.80 \\ [0.65] \\ 0.81 \\ [0.46] \\ 1.037 \\ 1.12 \\ 0.81 \\ 0.46 \\ 1.42 \\ 0.81 \\ 0.46 \\ 1.42 \\ 0.81 \\ 0.41 \\ 0.51 \\ 0.81 \\ 0.34 \\ 0.132 \\ 2.10 \\ 0.85 \\ 0.34 \\ 2.10 \\ 0.98 \\ 0.91 \\ 0.90 \\ 0.80 \\ 0.90 \\ 0.80 \\ 1.02 \\ 0.90 \\ 0.80 \\ 0.90 \\ 0.80 \\ 1.02 \\ 0.91 \\ 0.90 \\$	
Cercek, 2021 310 Chang, 2017 22 Willauer, 2019, AACR 220 Ugai, 2024 29 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowabj, 2023 785 Myer, 2022, European 2697 Lipsvs-Shart, 2022 93 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 12 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	730 63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	302 567 631 87 521 7288 21 37 2553 2053 2015 365 2143 8947	626 1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	3.3% 1.2% 3.4% 1.1% 0.6% 4.6% 0.5% 4.2% 4.2% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.79 \begin{array}{[} 0.64 \\ 0.99 \end{array} \\ 0.80 \begin{array}{[} 0.47 \\ 0.65 \\ 0.98 \end{array} \\ 0.81 \begin{array}{[} 0.46 \\ 0.55 \\ 0.98 \end{array} \\ 0.81 \begin{array}{[} 0.46 \\ 1.42 \end{array} \\ 0.82 \begin{array}{[} 0.76 \\ 0.82 \end{array} \\ 0.84 \begin{array}{[} 0.37 \\ 0.76 \\ 0.82 \end{array} \\ 0.84 \begin{array}{[} 0.32 \\ 2.20 \end{array} \\ 0.85 \begin{array}{[} 0.34 \\ 0.30 \end{array} \\ 0.86 \begin{array}{[} 0.76 \\ 0.98 \end{array} \\ 0.95 \begin{array}{[} 0.34 \\ 0.30 \end{array} \\ 0.95 \begin{array}{[} 0.96 \\ 0.95 \end{array} \\ 0.99 \begin{array}{[} 0.89 \\ 0.99 \end{array} \\ 0.99 \begin{array}{[} 0.80 \\ 0.99 \end{array} \\ 0.99 \begin{array}{[} 0.80 \\ 0.99 \end{array} \\ 0.90 \begin{array}{[} 0.80 \\ 0.95 \end{array} \\ 0.90 \begin{array}{[} 0.80 \\ 0.91 \end{array} \\ 0.90 \begin{array}{[} 0.80 \\ 0.90 \end{array} \\ 0.80 \end{array} \\ 0.90 \begin{array}{[} 0.80 \\ 0.91 \end{array} \\ 0.90 \begin{array}{[} 0.80 \\ 0.80 \end{array} \\ 0.91 \end{array} $	
Chang, 2017 22 Willauer, 2019, AACR 220 Chi, 2024 230 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowaty, 2023 765 Myer, 7022, European 2697 Lipsyc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2021 231 Myer, 7022, African 616 Furuhashi, 2023 10 Chen, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	63 528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	567 631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	1412 1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	1.2% 3.4% 1.1% 0.6% 4.6% 0.5% 4.2% 4.2% 4.4% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.80 \ [0.47, 1.36]\\ 0.80 \ [0.46, 1.42]\\ 0.81 \ [0.46, 1.42]\\ 0.81 \ [0.37, 1.78]\\ 0.82 \ [0.76, 0.89]\\ 0.84 \ [0.32, 2.20]\\ 0.85 \ [0.34, 2.10]\\ 0.86 \ [0.76, 0.98]\\ 0.89 \ [0.80, 1.00]\\ 0.99 \ [0.80, 1.00]\\ 0.90 \ [0.85, 0.95]\\ 0.90 \ [0.80, 1.17]\\ 0.$	
Willauer, 2019, AACR 220 Chi, 2024 29 Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holewathj, 2023 785 Myer, 2022, European 2697 Lipsyc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 12 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 154	528 67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	631 87 521 7288 21 37 2553 2016 11536 365 2143 8947	1340 179 1237 16235 40 158 6931 4418 22932 1355 6629	3.4% 1.1% 0.8% 4.8% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	$\begin{array}{c} 0.80 & [0.65, 0.98]\\ 0.81 & [0.46, 1.42]\\ 0.81 & [0.37, 1.78]\\ 0.82 & [0.76, 0.89]\\ 0.84 & [0.32, 2.20]\\ 0.85 & [0.34, 2.10]\\ 0.86 & [0.76, 0.98]\\ 0.89 & [0.80, 1.00]\\ 0.90 & [0.85, 0.95]\\ 0.90 & [0.89, 1.17]\\ 0.90 & [0.80, 1.07]\end{array}$	
Chi, 2024 29 Ugai, 2022 10 Gao, 2022 12727 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2697 Lipsvc-Shart, 2022 93 Jin, 2021 231 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	67 27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	87 521 7288 21 37 2553 2016 11536 365 2143 8947	179 1237 16235 40 158 6931 4418 22932 1355 6629	1.1% 0.6% 0.5% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	0.81 [0.46, 1.42] 0.81 [0.37, 1.78] 0.82 [0.76, 0.89] 0.84 [0.32, 2.20] 0.85 [0.34, 2.10] 0.86 [0.76, 0.98] 0.89 [0.80, 1.00] 0.90 [0.85, 0.95] 0.90 [0.89, 1.17] 0.90 [0.80, 1.02]	
Ugai, 2022 10 Gao, 2022 1272 Emiloju, 2023 144 Xicola, 2014 7 Ugai, 2023, MS8 tumors 408 Holowaty, 2023 765 Myer, 7022, European 2697 Lipsyc-Shart, 2022 93 Jin, 2021 497 Yozer, 2021 2391 Myer, 7022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	27 3171 29 34 1221 1832 5669 373 1649 5729 1063 40	521 7288 21 37 2553 2016 11536 365 2143 8947	1237 16235 40 158 6931 4418 22932 1355 6629	0.6% 4.6% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	0.81 [0.37, 1.78] 0.82 [0.76, 0.89] 0.84 [0.32, 2.20] 0.85 [0.34, 2.10] 0.86 [0.76, 0.98] 0.89 [0.80, 1.00] 0.90 [0.85, 0.96] 0.90 [0.89, 1.17] 0.90 [0.80, 1.02]	
Gao, 2022 1272 Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2687 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 427 Alzaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 154	3171 29 34 1221 1832 5669 373 1649 5729 1063 40	7288 21 37 2553 2016 11536 365 2143 8947	16235 40 158 6931 4418 22932 1355 6629	4.6% 0.5% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	0.82 [0.76, 0.89] 0.84 [0.32, 2.20] 0.85 [0.34, 2.10] 0.86 [0.76, 0.88] 0.89 [0.80, 1.00] 0.90 [0.85, 0.96] 0.90 [0.69, 1.17] 0.90 [0.80, 1.02]	
Emiloju, 2023 14 Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowatyi, 2023 785 Myer, 2022, European 2697 Lipsve-Shart, 2022 93 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	29 34 1221 1832 5669 373 1649 5729 1063 40	21 37 2553 2016 11536 365 2143 8947	40 158 6931 4418 22932 1355 6629	0.5% 0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	0.84 (0.32, 2.20) 0.85 (0.34, 2.10) 0.86 (0.76, 0.98) 0.89 (0.80, 1.00) 0.90 (0.85, 0.95) 0.90 (0.69, 1.17) 0.90 (0.80, 1.02)	
Xicola, 2014 7 Ugai, 2023, MSS tumors 408 Holowath, 2023 785 Myer, 2022, European 2697 Lipsyc-Shart, 2022 93 Jin, 2021 497 Yozer, 2021 2391 Myer, 7022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	34 1221 1832 5669 373 1649 5729 1063 40	37 2553 2016 11536 365 2143 8947	158 6931 4418 22932 1355 6629	0.5% 4.2% 4.4% 4.8% 2.8% 4.3%	0.85 (0.34, 2.10) 0.86 (0.76, 0.98) 0.89 (0.80, 1.00) 0.90 (0.85, 0.95) 0.90 (0.69, 1.17) 0.90 (0.80, 1.02)	
Ugai, 2023, MSS tumors 408 Holewahj, 2023 785 Myer, 2022, European 2697 Lipsyc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2023 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	1221 1832 5669 373 1649 5729 1063 40	2553 2016 11536 365 2143 8947	6931 4418 22932 1355 6629	4.2% 4.4% 4.8% 2.8% 4.3%	0.86 (0.76, 0.98) 0.89 (0.80, 1.00) 0.90 (0.85, 0.95) 0.90 (0.69, 1.17) 0.90 (0.80, 1.02)	
Holowahj, 2023 785 Myer, 2022, European 2697 Lipsve-Shart, 2022 933 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	1832 5669 373 1649 5729 1063 40	2016 11536 365 2143 8947	4418 22932 1355 6629	4.4% 4.8% 2.8% 4.3%	0.89 [0.80, 1.00] 0.90 [0.85, 0.95] 0.90 [0.69, 1.17] 0.90 [0.80, 1.02]	
Myer, 2022, European 2697 Lipsyc-Sharf, 2022 93 Jin, 2021 497 Ozer, 2021 2381 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	5669 373 1649 5729 1063 40	11536 365 2143 8947	22932 1355 6629	4.8% 2.8% 4.3%	0.90 [0.85, 0.95] 0.90 [0.69, 1.17] 0.90 [0.80, 1.02]	
Lipsyc-Shart, 2022 93 Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546	373 1649 5729 1063 40	365 2143 8947	1355 6629	2.8% 4.3%	0.90 [0.69, 1.17] 0.90 [0.80, 1.02]	+
Jin, 2021 497 Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	1649 5729 1063 40	2143 8947	6629	4.3%	0.90 [0.80, 1.02]	
Ozer, 2021 2391 Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	5729 1063 40	8947				
Myer, 2022, African 616 Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	1063 40		20366	4.0.07	0.91 (0.86, 0.97)	+
Furuhashi, 2023 10 Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	40	2091		4.8%		
Chen, 2022a 427 Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156			3482	4.1%	0.92 [0.80, 1.05]	-+-
Al Zaabi, 2023 17 Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 156	9/7	75	289	0.7%	0.95 [0.44, 2.04]	
Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546	347	1614	3521	4.0%	0.97 [0.84, 1.12]	-
Meng, 2023 92 Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546	41	27	64	0.6%	0.97 [0.44, 2.15]	
Pereira, 2020 108 Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546	196	256	540	2.3%	0.98 [0.71, 1.36]	
Araujo, 2021 490 Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546		700	1377	2.6%	1.04 [0.78, 1.40]	
Du, 2023 12 Willauer, 2019, MDACC 313 Aljehani, 2023 1546		1864	3897	4.1%	1.05 [0.91, 1.20]	
Willauer, 2019, MDACC 313 Aljehani, 2023 1546		19	49	0.5%	1.05 [0.42, 2.67]	
Aljehani 2023 1546		596	1243	3.6%	1.06 [0.87, 1.28]	
		7311	18937	4.7%	1.07 [1.00, 1.15]	+
		34	10357	0.9%	1.20 [0.64, 2.25]	
	77	34 127	263			
				1.3%	1.22 [0.73, 2.03]	
Andric, 2023 10		9	20	0.3%	1.22 [0.35, 4.24]	
Kirzin, 2014, MSI tumors 3		4	14	0.1%	1.25 [0.21, 7.62]	
Gausman, 2020 47		20	49	0.8%	1.34 [0.67, 2.67]	
Li, 2022a 20		51	99	0.6%	1.34 [0.61, 2.96]	
Kuchel, 2021 21	39	58	127	0.8%	1.39 [0.68, 2.85]	
Alvarez, 2021 13		48	162	0.7%	1.54 [0.71, 3.35]	
Tricoli, 2018 11	31	7	30	0.3%	1.81 [0.59, 5.55]	
Perez-Mayoral, 2023 20		26	96	0.7%	1.92 [0.93, 3.99]	
Spolverato, 2023 6	15	20	79	0.3%	1.97 [0.62, 6.22]	
Gardner, 2021 9	20	3	12	0.2%	2.45 [0.51, 11.87]	
Pilozzi, 2015 9	21	4	21	0.2%	3.19 [0.79, 12.80]	
Ugai, 2023, MSI tumors 78	217	167	1184	2.3%	3.42 [2.48, 4.72]	
Magnani, 2015 9	25	4	41	0.3%	5.20 (1.40, 19.39)	
Escrobar, 2020, MSI tumors 5	7	4	30	0.1%	16.25 [2.32, 114.06]	
Total (95% CI)	32854		137764	100.0%	0.91 [0.85, 0.98]	•
Total events 13932		61254				
Heterogeneity: Tau ² = 0.02; Chi ² = 193.2 Test for overall effect: Z = 2.57 (P = 0.01)		P < 0.0000	1); I² = 70	%	-	0.2 0.5 1 2 5

FIGURE 2

Odds ratios for *KRAS* mutation in early-onset CRC. Data presented as odds ratios (95% confidence interval) for *KRAS* mutation in early-onset relative to late-onset colorectal cancer. The pooled odds ratio is obtained via a random effects model using inverse variance weighting. AACR, American Association for Cancer Research; MDACC, MD Anderson Cancer Center; MSI, microsatellite instability; MSS, microsatellite stable.

(20); *PIK3CA* mutation (21); *PTEN* mutation (8); *HER2* amplifications (5); *APC* mutation (19); *TP53* mutation (20). For early-onset CRC, there is evidence for a significantly lower prevalence of mutations in *KRAS* (Figure 2, OR 0.91, 95% CI 0.85-0.98), *BRAF* (Figure 3, OR 0.63, 95% CI 0.51-0.78) and *APC* (Figure 4, OR 0.70, 95% CI 0.58-0.84) compared to late-onset CRC. Early-onset CRC was associated with non-significantly lower prevalence of mutations in *NRAS* (Figure 5, OR 0.88, 95% CI 0.78-1.00, p = .06). Conversely, early-onset CRC is associated with a higher prevalence of mutations in *TP53* (Figure 6, OR 1.34, 95% CI 1.24-1.45) and *PTEN* (Figure 7, OR 1.68, 95% CI 1.04-2.73). There was no significant difference in the prevalence of *PIK3CA* mutations (Supplementary Figure S1, OR 0.95, 95% CI 0.86-1.05), or *HER2* amplifications (Supplementary Figure S2, OR 1.64, 95% CI 0.86-3.14). Significant inter-study heterogeneity

was observed for mutations in *KRAS*, *BRAF*, *PTEN*, and *APC*. Hazard ratios for oncogene mutations were stable in the leave-one-out sensitivity analysis (Supplementary Table S3), although the association for *NRAS* and *PTEN* mutations did not always reach statistical significance.

Fifty studies were identified that specifically excluded individuals with Lynch syndrome or family history of CRC, or that restricted the analysis to individuals with microsatellite stable tumors (Table 1; Supplementary Table S2). Compared to the full analysis, the association between early-onset CRC and *BRAF* (OR 0.77, 95% CI 0.64-0.92) and *APC* mutations (OR 0.81, 95% CI 0.67-0.97) were attenuated but remained statistically significant, while the associations with *KRAS*, *NRAS*, and *TP53* mutations were similar. Further, an inverse association between early-onset CRC

Study or Subgroup	Early-ons Events	Total	Late-onse Events		Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
Pilozzi, 2015	Lvents 0	22	Lvents 0	21	rogn	Not estimable	in the second seco
Escobar, 2020, MSI tumors	0	7	21	30	0.5%	0.03 [0.00, 0.57]	←─────
Ugai, 2023, MSI tumors	15	493	716	1425	2.7%	0.03 [0.02, 0.05]	+
Perea, 2014, MSI tumors	0	12	4	9	0.4%	0.05 [0.00, 1.07]	←
Kirzin, 2014, MSS tumors	0	39	5	36	0.5%	0.07 [0.00, 1.36]	←
Chouhan, 2019	Ū.	57	46	434	0.5%	0.07 [0.00, 1.20]	←
Altshuler, 2023	1	67	41	254	0.9%	0.08 [0.01, 0.58]	←
Kirzin, 2014, MSI tumors	0	9	5	14	0.4%	0.09 [0.00, 1.88]	←
Alvarez, 2021	0	28	21	146	0.5%	0.10 [0.01, 1.74]	←
Eachkoti, 2018	1	22	11	35	0.8%	0.10 [0.01, 0.87]	←
Martinez-Perez, 2023	1	37	75	385	0.9%	0.11 [0.02, 0.85]	·
Xicola, 2014	0	68	16	340	0.5%	0.14 [0.01, 2.42]	· · · · · · · · · · · · · · · · · · ·
Tan, 2022	23	163	333	640	2.8%	0.15 [0.09, 0.24]	
Storandt, 2023	3	73	25	114	1.6%	0.15 [0.04, 0.53]	
Magnani, 2015	0	25	4	41	0.5%	0.16 [0.01, 3.17]	
Laskar, 2015	0	42	2	38	0.4%	0.17 [0.01, 3.69]	·
Kanter, 2021	9	133	49	256	2.4%	0.31 [0.15, 0.65]	
Gardner, 2021 Tricoli, 2019	2	20 31	3 7	12 30	0.9% 1.3%	0.33 [0.05, 2.37] 0.35 [0.08, 1.52]	,
Tricoli, 2018 Jin, 2021	3 107	31 1919	/ 1067	30 7629	1.3%	0.36 [0.30, 0.45]	
Jin, 2021 Emiloju, 2023	107	32	1067	7629	3.2%	0.38 [0.30, 0.45]	
Ugai, 2022	2	27	204	1311	1.1%	0.43 [0.10, 1.85]	
Perea, 2014, MSS tumors	1	60	204	88	0.7%	0.48 [0.05, 4.73]	
Spolverato, 2023	1	15	10	79	0.8%	0.49 [0.06, 4.17]	
Jeong, 2022	4	77	26	263	1.8%	0.50 [0.17, 1.48]	
Lipsyc-Sharf, 2022	18	173	112	688	2.7%	0.60 [0.35, 1.01]	
Cercek, 2021	38	730	52	626	2.9%	0.61 [0.39, 0.93]	
Dharwadkar, 2021	2	57	7	124	1.2%	0.61 [0.12, 3.02]	
Meng, 2023	15	196	64	540	2.6%	0.62 [0.34, 1.11]	
Mueller, 2021	3	32	14	101	1.5%	0.64 [0.17, 2.40]	
Myer, 2022, European	239	5669	1469	22932	3.2%	0.64 [0.56, 0.74]	
Willauer, 2019, MDACC	37	634	107	1243	2.9%	0.66 [0.45, 0.97]	
Lieu, 2019	74	1420	1043	13550	3.1%	0.66 [0.52, 0.84]	
Pereira, 2020	8	207	78	1360	2.4%	0.66 [0.31, 1.39]	
Susanti, 2021	4	50	21	181	1.8%	0.66 [0.22, 2.03]	· · · · · · · · · · · · · · · · · · ·
Raimondi, 2022	1 12	35 170	8 82	194 833	0.8% 2.6%	0.68 [0.08, 5.64]	
Antoniotti, 2022 Kuchel, 2021	4	34	82 16	833	2.0%	0.70 [0.37, 1.31] 0.72 [0.22, 2.31]	
Escobar, 2020, MSS tumors	4	34	10	134	1.2%	0.75 [0.16, 3.60]	
Holowatyj, 2023	125	1832	381	4418	3.1%	0.78 [0.63, 0.96]	
Myer, 2022, African	18	1063	74	3482	2.7%	0.79 [0.47, 1.33]	
Ugai, 2023, MSS tumors	104	1979	498	7751	3.1%	0.81 [0.65, 1.00]	
Willauer, 2019, AACR	53	528	160	1340	3.0%	0.82 [0.59, 1.14]	
Perez-Mayoral, 2023	4	43	9	91	1.6%	0.93 [0.27, 3.22]	
Chen, 2022a	28	947	99	3521	2.9%	1.05 [0.69, 1.61]	
Khan, 2016	8	94	22	275	2.2%	1.07 [0.46, 2.49]	
Chang, 2017	3	63	59	1412	1.7%	1.15 [0.35, 3.76]	
Al Zaabi, 2023	1	18	2	42	0.6%	1.18 [0.10, 13.86]	
Gao, 2022	113	3029	506	16106	3.2%	1.19 [0.97, 1.47]	+
Chen, 2021	8	87	14	199	2.1%	1.34 [0.54, 3.32]	— <u> </u>
Ye, 2015	3	47	17	403	1.6%	1.55 [0.44, 5.49]	
Wang, 2021a	3	29	3	46	1.1%	1.65 [0.31, 8.81]	
Doleschal, 2023	4	41	2	36	1.0%	1.84 [0.32, 10.68]	
Bisht, 2014	10	67	10	134	2.0%	2.18 [0.86, 5.52]	
Foppa, 2022a	5	117	8	421	1.7%	2.30 [0.74, 7.18]	
Xu, 2020	36	330	5	110	2.0%	2.57 [0.98, 6.73]	
Andric, 2023	5	20	2	20	1.0%	3.00 [0.51, 17.74]	
Furuhashi, 2023	3	40	7	289	1.4%	3.27 [0.81, 13.18]	
Chi, 2024	6	67	5	179	1.6%	3.42 [1.01, 11.62]	
Aldiab, 2017	27	78	12	97	2.3%	3.75 [1.75, 8.05]	
Total (95% CI)		23439		96650	100.0%	0.63 [0.51, 0.78]	◆
Total events	1199		7678				-
Heterogeneity: Tau ² = 0.38; C		df = 58 (F		1); I² = 84	%		0.05 0.2 1 5 20
Test for overall effect: Z = 4.17							0.05 0.2 1 5 20 Less common in EO-CRC More common in EO-CRC

Odds ratios for *BRAF* mutation in early-onset CRC. Data presented as odds ratios (95% confidence interval) for *BRAF* mutation in early-onset relative to late-onset colorectal cancer. The pooled odds ratio is obtained via a random effects model using inverse variance weighting. AACR, American Association for Cancer Research; MDACC, MD Anderson Cancer Center; MSI, microsatellite instability; MSS, microsatellite stable.


and *PIK3CA* mutation was also observed (OR 0.88, 95% CI 0.78-0.99).

3.2 Molecular carcinogenesis pathways

There were 10 studies that compared the prevalence of CIMPhigh status in early- vs. late-onset CRC, and 64 studies that compared MSI status. Individuals with early-onset CRC had significantly lower odds for CIMP-high tumors compared to individuals with late-onset disease (Supplementary Figure S3, OR 0.24, 0.10-0.57), but significantly higher odds for the MSI phenotype (Supplementary Figure S4, OR 1.31, 1.11-1.56). Significant heterogeneity was observed for both markers. Associations were stable in the leave-one-out sensitivity analysis (Supplementary Table S3), and after limiting the analysis to studies that excluded individuals with Lynch syndrome or family history of CRC (Table 1).

3.3 Histological characteristics

There were 86 studies that compared the prevalence of highgrade tumors (i.e. poorly differentiated or undifferentiated tumors) in early- vs. late-onset CRC, 57 studies that compared the prevalence of mucinous histology (or mucinous characteristics), and 44 studies that reported on signet ring cell carcinomas. In earlyonset CRC, there was evidence for a significantly higher prevalence



Odds ratios for APC mutation in early-onset colorectal cancer. Data presented as odds ratios (95% confidence interval) for APC mutation in earlyonset relative to late-onset colorectal cancer. The pooled odds ratio is obtained via a random effects model using inverse variance weighting. AACR, American Association for Cancer Research; COH, City of Hope National Medical Center; CI, confidence interval; EO-CRC, early-onset colorectal cancer; MDACC, MD Anderson Cancer Center; MSKCC, Memorial Sloan Kettering Cancer Center; UCD, University of California, Davis.

of high-grade (i.e., poorly differentiated) tumors (Supplementary Figure S5, OR 1.20, 95% CI 1.15-1.25), as well as mucinous tumors (Supplementary Figure S6, OR 1.22, 95% CI 1.16-1.27), and signet ring cell carcinomas (Supplementary Figure S7, OR 2.32, 2.08-2.57). Significant inter-study heterogeneity was observed for all histological markers. All associations were stable in the leave-one-out sensitivity analysis (Supplementary Table S3) and after limiting the analysis to studies that excluded individuals with Lynch syndrome or family history of CRC (Table 1).

3.4 Immune markers

There have been nine studies to investigate age differences in the immune cell populations of CRC tumors, with inconsistent results (49-57). Du et al. reported that Chinese patients with sporadic early-onset CRC showed significantly higher densities of multiple immune cell populations in the tumor microenvironment compared to patients with late-onset disease, including higher levels of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells (50). By contrast, Ugai et al. reported no significant differences in the populations of T cells, macrophages, and other myeloid cells in participants with early- vs. late-onset CRC from the Nurses' Health Study and Health Professionals Follow-up Study (51). In a small study of 14 tumors utilizing single cell RNA sequencing, Li et al. reported that earlyonset CRC was associated with lower levels of effector CD8+ T cells and antigen-presentation in the tumor microenvironment, but higher levels of naïve CD8+ T cells and immunosuppressive regulatory T cells compared to individuals with late-onset disease, suggesting an impaired anti-tumor immune response for earlyonset CRC (54). Because MSI status may influence the anti-tumor immune response, recent studies have examined associations between early-onset CRC and tumor lymphocyte populations in samples limited to microsatellite stable tumors, or after careful exclusion of participants with Lynch syndrome (56, 57). In a matched analysis of microsatellite stable tumors, Lu et al. (2023) reported that there was no significant differences between early- and late-onset CRC for the infiltration of 22 different lymphocyte populations in the tumor microenvironment (57). Likewise, Andric et al. found no significant difference for five lymphocyte populations (total T cells, conventional CD4+ and CD8+ T cells, regulatory T cells, and $\gamma\delta$ T cells) in a matched sample limited to cases of sporadic CRC (56). Other studies have reported no significant differences between early and late-onset CRC for the density of total tumor infiltrating lymphocytes (53, 55).

3.5 The consensus molecular subtypes

There have been six studies to determine the distribution of consensus molecular subtypes (CMS) for CRC by age at diagnosis (50, 57-61). Utilizing tumor tissues samples from 626 individuals diagnosed with CRC from The Cancer Genome Atlas and MD Anderson Cancer Center, Willauer reported that the CMS1 subtype was more common among patients aged 30-39 years at diagnosis (46%) compared to older participants, while the CMS4 subtype was less common (13%) (58). Conversely, in a smaller study from the Nanjing Colorectal Cancer Cohort, Du et al. reported a higher prevalence of the CMS4 subtype in early- vs. late-onset CRC (36.7% vs. 12.2%, respectively), although the comparison between age groups did not reach statistical significance (50). Recent results, including from a small sample of South Korean participants (59) and additional analyses of The Cancer Genome Atlas (60, 61) did not show any significant association between early-onset tumors and the distribution of consensus molecular subtypes.




FIGURE 5

Odds ratios for *NRAS* mutation in early-onset colorectal cancer. Data presented as odds ratios (95% confidence interval) for *NRAS* mutation in earlyonset relative to late-onset colorectal cancer. The pooled odds ratio is obtained via a random effects model using inverse variance weighting. AACR, American Association for Cancer Research; CI, confidence interval; EO-CRC, early-onset colorectal cancer; MDACC, MD Anderson Cancer Center.

4 Discussion


Sporadic early-onset CRC is a significant public health concern, increasing by 2-3% per year in the U.S. since 1990 (3, 62). Early-onset CRC is more often diagnosed at advanced stages compared to late-onset disease (63, 64). However, there is inconsistent evidence that survival varies between early- and late-onset CRC (65, 66), complicated by reports that younger patients receive more aggressive systemic treatment (67–69). Thus, international guidelines do not endorse separate treatment recommendations

for early-onset disease (70). Investigating the associations between early-onset tumors and molecular and histological characteristics, and novel tumor markers including immune cell populations, may help to guide the development of therapies that benefit early-onset CRC. Further, highlighting associations between early-onset CRC and tumor markers may aid in the design of clinical trials for targeted therapies. To the authors' knowledge, this is the first comprehensive systematic review and meta-analysis of tumor prognostic and predictive markers in early-onset CRC. We found that early-onset CRC was associated with a lower prevalence of

	Early-onse		Late-ons			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Kirzin, 2014, MSI tumors	0	9	5	14	0.1%	0.09 [0.00, 1.88]	←
Escobar, 2020, MSI tumors	1	7	9	30	0.1%	0.39 [0.04, 3.71]	· · · · · · · · · · · · · · · · · · ·
Li, 2022a	20	34	77	99	0.9%	0.41 [0.18, 0.94]	
Kirzin, 2014, MSS tumors	17	39	17	36	0.7%	0.86 [0.35, 2.15]	
Chang, 2017	17	63	413	1412	1.8%	0.89 [0.51, 1.58]	
Jeong, 2022	62	77	215	263	1.4%	0.92 [0.48, 1.76]	
Willauer, 2019, MDACC	413	634	801	1243	8.9%	1.03 [0.84, 1.26]	- + -
Wang, 2021a	19	29	29	46	0.6%	1.11 [0.42, 2.94]	
Furuhashi, 2023	25	40	169	289	1.3%	1.18 [0.60, 2.34]	
Lipsyc-Sharf, 2022	57	169	200	674	3.9%	1.21 [0.84, 1.73]	
Willauer, 2019, AACR	378	528	877	1340	7.9%	1.33 [1.07, 1.66]	
Du, 2023	21	30	31	49	0.6%	1.35 [0.51, 3.59]	
Holowatyj, 2023	1460	1832	3270	4418	13.1%	1.38 [1.21, 1.57]	-
Tricoli, 2018	19	31	16	30	0.6%	1.39 [0.50, 3.84]	
Myer, 2022, European	4676	5669	17711	22932	17.6%	1.39 [1.29, 1.50]	+
Lieu, 2019	1169	1420	10393	13550	12.4%	1.41 [1.23, 1.63]	
Laskar, 2015	19	42	14	38	0.7%	1.42 [0.58, 3.47]	
Myer, 2022, African	866	1063	2615	3482	10.4%	1.46 [1.23, 1.73]	
Meng, 2023	153	196	381	540	3.5%	1.48 [1.01, 2.18]	
Escobar, 2020, MSS tumors	26	35	88	134	0.8%	1.51 [0.65, 3.49]	
Kim, 2021	194	241	1054	1462	4.3%	1.60 [1.14, 2.24]	│ _ • _
Cercek, 2021	599	730	461	626	6.4%	1.64 [1.26, 2.12]	│
Chi, 2024	44	67	90	179	1.7%	1.89 [1.06, 3.39]	
Perea, 2021	9	17	8	33	0.4%	3.52 [1.02, 12.16]	
Total (95% CI)		13002		52919	100.0%	1.34 [1.24, 1.45]	•
Total events	10264		38944				
Heterogeneity: Tau ² = 0.01; C	hi ² = 32.64. d	f= 23 (P	= 0.09); ² :	= 30%			0.1 0.2 0.5 1 2 5 10

FIGURE 6

Odds ratios for *TP53* mutation in early-onset colorectal cancer. Data presented as odds ratios (95% confidence interval) for *TP53* mutation in earlyonset relative to late-onset colorectal cancer. The pooled odds ratio is obtained via a random effects model using inverse variance weighting. AACR, American Association for Cancer Research; CI, confidence interval; EO-CRC, early-onset colorectal cancer; MDACC, MD Anderson Cancer Center; MSI, microsatellite instability; MSS, microsatellite stability.



oncogene mutations in *KRAS*, *BRAF*, *NRAS*, and *APC*, but a higher prevalence of *TP53* and *PTEN* mutations and adverse histologic subtypes, with inconsistent associations for immune cell populations and the consensus molecular subtypes.

KRAS, BRAF, and NRAS encode proteins that act downstream of the epidermal growth factor receptor (EGFR) and activate Mek/ Erk signaling (21, 71). Mutations in these oncogenes are negative predictive markers for EGFR inhibition in metastatic CRC (17, 18) and are associated with inferior survival outcomes across tumor stage (19, 20, 23, 72), including for early-onset CRC (73-75). Earlyonset CRC is associated with a lower prevalence of mutations in these genes compared to late-onset disease, indicating that individuals with metastatic early-onset CRC may be more likely to benefit from EGFR inhibition. Notably, the association with NRAS mutations was not statistically significant, which may be due to the scarcity of this marker (76). Further, the association with BRAF mutation was attenuated but still statistically significant in studies that excluded individuals with Lynch syndrome, who are less likely to have BRAF mutations compared to sporadic disease (77). Further, this sensitivity analysis revealed an inverse association with PIK3CA mutation, which has also been linked to higher risk for mortality and resistance to EGFR inhibition (17, 78). Conversely, early-onset CRC was associated with a higher proportion of mutations in tumor suppressor PTEN, which encodes a lipid-phosphatase that suppresses the activity of PI3k/ Akt/mTOR signaling and interacts with the EGFR pathway (27). Loss of PTEN activity has been linked to resistance to EGFR inhibition in metastatic CRC (79) but is not currently used in clinical decision making. Pharmaceutical therapies to restore normal PTEN activity are under development but have not been evaluated in CRC. Early-onset CRC was associated with a significantly higher prevalence of TP53 mutations, which cause loss of p53 tumor suppressor activity and pro-tumorigenic gain of function effects that accelerate cell proliferation, angiogenesis, and metastasis (80). TP53 mutations are found in approximately 60% of tumors and may promote resistance to EGFR inhibitors and chemotherapies that rely on wild type p53 to induce cellular apoptosis (e.g. 5-fluorouracil and Oxaliplatin) (29). Consequently, targeted therapies to restore wild type p53 activity or degrade mutant p53, or to inhibit downstream effector pathways, are

currently being investigated in clinical trials (81). Potentially, individuals with early-onset CRC may be more likely to benefit from treatments that inhibit pro-tumorigenic p53 activity and should be targeted for enrollment in these trials.

Early-onset CRC was associated with a lower prevalence of APC mutation, a key driver of the canonical adenoma-carcinoma pathway (82). APC mutations are present in approximately 80% of CRC tumors (11, 12, 14), and recent evidence indicates that APC-mutant tumors are associated with extended overall and progression-free survival compared to wild type (30, 31) (5). Notably, the association with APC mutation was attenuated but still statistically significant when limiting the analysis to studies that excluded individuals with Lynch syndrome, or that included microsatellite stable tumors only. Individuals with early-onset CRC had a higher prevalence of MSI, defined by a high density of somatic mutations in short, non-coding sequences caused by defects in DNA mismatch repair (40). MSI is associated with lower risk for overall mortality and distant metastases compared to microsatellite stable tumors, including in early-onset CRC (75). Further, MSI tumors secrete truncated proteins that trigger an anti-tumor immune response (83), and consequently MSI is a positive predictor for response to immune checkpoint inhibitors (83). Our findings therefore highlight the importance of MSI testing for individuals younger than 50, in accordance with clinical guidelines (70). Unexpectedly, the association between early-onset CRC and MSI status was modestly strengthened in studies that excluded individuals with known Lynch syndrome, which causes tumors with MSI (84). Because a significant proportion of individuals with Lynch syndrome may be unaware of the condition (85), it is possible that the exclusion of Lynch syndrome was incomplete in some studies. Early-onset CRC was associated with a lower prevalence of the CpG island methylator phenotype (CIMP), characterized by methylation and inactivation of tumor-suppressor genes (86). Although CIMP has been linked to poor prognosis in multiple studies, it currently has limited value as a prognostic marker due to a lack of standardized assessment and competing effects of MSI and BRAF mutation, which are associated with CIMP (41).

We also found that early-onset CRC is associated with higher odds for tumors with more aggressive histological features, including poorly differentiated tumors, mucinous carcinomas, and signet ring cell carcinomas (38, 87). The association with signet ring features was especially pronounced (OR [95% CI]: 2.32 [2.08-2.57]). Although signet ring carcinomas comprise only 1% of CRC tumors (39), this feature is present in 2-3% of early-onset tumors. A recent meta-analysis showed that signet ring carcinomas were associated with significantly higher risk for overall mortality and recurrence compared to conventional adenocarcinomas (88). Results were similar for mucinous tumors, which comprise approximately 10-15% of CRCs (89). The associations between histological subtypes and colorectal cancer mortality, especially poorly differentiated tumors and signet ring carcinomas, have been validated in early-onset CRC (90–93). Currently, there are no treatments that specifically target mucinous or signet ring cell carcinomas and treatment guidelines do not distinguish between histological subtypes (70).

The observed associations between early-onset CRC and certain histological and molecular tumor characteristics may be explained in part by differences in tumor location (94). Approximately 30% of early-onset tumors are located in the rectum, versus 20% of lateonset tumors (64, 95). KRAS, BRAF, PIK3CA, and NRAS mutations are enriched in proximal tumors (96, 97) while TP53 mutations are enriched in rectal tumors (98). Notably, studies that were limited to individuals with tumors in the distal colon or rectum have not shown a consistent association between early-onset CRC and the presence of oncogene mutations (46, 55, 56, 99-102). For example, a study with more than 1,000 distal and rectal tumors showed no significant age difference in KRAS, BRAF, NRAS, PIK3CA, TP53, or APC mutations (46). Conversely, in a large-scale analysis with detailed stratification by tumor location, Ugai et al. found that early-onset CRC had a lower prevalence of BRAF mutations for all tumor sites except the sigmoid colon and rectum (103). Notably, aggressive histological subtypes are overrepresented in the proximal colon (104), and consequently the association with early-onset CRC is not explained by differences in tumor location.

We found inconsistent evidence linking early-onset CRC to differences in 'novel' tumor prognostic and predictive markers including populations of immune cells in the tumor microenvironment (8). A recent meta-analysis demonstrated that a higher density of tumor infiltrating lymphocytes was associated with reduced overall mortality among 20,015 individuals with CRC (HR [95% CI]: 0.65 [0.54-0.77]) (42), while others have shown that an 'immunoscore' encompassing cytotoxic T cells and CD3+ cells was a superior prognostic marker compared to the tumor stage (105, 106). Currently, the association between early-onset CRC and the anti-tumor immune response has been inconsistent (48-50, 52, 53, 55, 56, 58). Notably, higher rates of MSI in early-onset CRC due to Lynch syndrome may obscure associations with immune markers in sporadic disease, as MSI tumors trigger a robust antitumor immune response (83). Studies limited to microsatellite stable tumors or that carefully excluded participants with hereditary syndromes have tended to show no significant differences in immune cell populations between early- and lateonset CRC (51, 56, 57). Likewise, there is currently no consistent evidence that the distribution of consensus molecular subtypes differs between early- and late-onset CRC, with most studies reporting null findings (50, 57, 59-61). The consensus molecular subtypes have shown to be a robust predictor of mortality outcomes independent of tumor stage (107), but to the authors' knowledge have not been validated specifically in early-onset CRC. Further, the identification of novel molecular subtypes in early-onset CRC based on tumor gene expression is an area for future research.

Strengths of this study include the comprehensive nature of the search strategy, as we were able to summarize the evidence for agerelated differences in the prevalence of established tumor prognostic markers as well as emerging markers including immune cell populations in the tumor microenvironment and the consensus molecular subtypes. Further, the large number of studies identified for most markers allowed for relatively precise estimates of the association with early-onset CRC. Lastly, to better understand the associations between early-onset CRC and tumor markers in sporadic disease, we completed a sensitivity analysis limited to studies that excluded individuals with known Lynch syndrome (or family history of CRC). This analysis is also attended by several limitations. Due to the breadth of the review, our literature search was limited to original research studies published within the last ten years in Pubmed. Consequently, it is possible that a relevant study was missed. However, this is unlikely to be a significant limitation given the paucity of large tumor genomic studies published prior to 2013 and the comprehensive nature of our search strategy. Further, there was evidence for significant heterogeneity in the estimates for most tumor markers, but we were unable to investigate underlying sources of inter-study heterogeneity because the prevalence of tumor prognostic markers was rarely presented in subgroups defined by tumor location, tumor stage, or MSI status. Between-study differences in the definitions of early- and late-onset CRC may also have contributed to heterogeneity, although we excluded studies where misclassification of early-onset CRC was apparent. Lastly, although we attempted to control for bias by performing a sensitivity analysis limited to studies that accounted for Lynch syndrome in the study design, it is possible that residual confounding by hereditary conditions or differences in tumor location may have biased the results.

5 Conclusions

In summary, early-onset CRC was associated with a lower prevalence of mutations in several oncogenes linked to mortality and poor therapeutic response, including KRAS, BRAF, and NRAS compared to individuals with late-onset disease. Conversely, earlyonset disease was associated with a higher prevalence of potentially harmful mutations in TP53 and PTEN, as well as aggressive histological subtypes including mucinous and signet ring cell carcinomas. In part, these associations may reflect the higher prevalence of rectal tumors in early-onset CRC and the effect of hereditary syndromes on tumor markers. Given these findings and the alarming rise in the incidence of early-onset CRC, it is essential that clinical trials for targeted therapies enroll sufficient numbers of individuals with early-onset disease to evaluate their efficacy in this subgroup. Additional research is required to clarify the relationships with novel tumor characteristics including immune markers and to identify molecular subtypes specific to early-onset CRC that can inform treatment and prognosis.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

TL: Writing – review & editing, Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation. LP: Writing – review & editing, Writing – original draft, Investigation, Data curation. SW: Writing – review & editing, Supervision, Resources, Project administration, Methodology, Funding acquisition, Conceptualization.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Cancer Institute of the National Institutes of Health [NIH/NCI] under grants R00 CA207848 and R01 CA255318.

References

1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. (2023). 73(3):233–54. doi: 10.3322/caac.21772

2. Weinberg BA, Marshall JL. Colon cancer in young adults: trends and their implications. *Curr Oncol Rep.* (2019) 21:3. doi: 10.1007/s11912-019-0756-8

3. Murphy CC, Singal AG, Baron JA, Sandler RS. Decrease in incidence of youngonset colorectal cancer before recent increase. *Gastroenterology*. (2018) 155:1716–9. doi: 10.1053/j.gastro.2018.07.045

4. Done JZ, Fang SH. Young-onset colorectal cancer: A review. World J Gastrointest Oncol. (2021) 13:856–66. doi: 10.4251/wjgo.v13.i8.856

5. Ballester V, Rashtak S, Boardman L. Clinical and molecular features of youngonset colorectal cancer. *World J Gastroenterol.* (2016) 22:1736–44. doi: 10.3748/ wjg.v22.i5.1736

6. Sagaert X, Vanstapel A, Verbeek S. Tumor heterogeneity in colorectal cancer: what do we know so far? *Pathobiology.* (2018) 85:72-84. doi: 10.1159/000486721

7. Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? *BioMed Res Int.* (2015) 2015:149014. doi: 10.1155/2015/149014

8. Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy. *Front Immunol.* (2021) 12:808964. doi: 10.3389/fimmu.2021.808964

9. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. *Nat Med.* (2015) 21:1350–6. doi: 10.1038/nm.3967

10. Lech G, Słotwiński R, Słotkowski M, Krasnodębski IW. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. *World J Gastroenterol.* (2016) 22:1745–55. doi: 10.3748/wjg.v22.i5.1745

11. Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, et al. The genomics of colorectal cancer in populations with african and european ancestry. *Cancer Discovery*. (2022) 12:1282–93. doi: 10.1158/2159-8290.CD-21-0813

12. Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, et al. Comprehensive genomic landscapes in early and later onset colorectal cancer. *Clin Cancer Res.* (2019) 25:5852–8. doi: 10.1158/1078-0432.CCR-19-0899

13. Gao XH, Li J, Liu LJ, Zheng NX, Zheng K, Mei Z, et al. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. *Int J Surg.* (2022) 104:106780. doi: 10.1016/j.ijsu.2022.106780

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2024.1349572/ full#supplementary-material

14. Holowatyj AN, Wen W, Gibbs T, Seagle HM, Keller SR, Edwards DRV, et al. Racial/ethnic and sex differences in somatic cancer gene mutations among patients with early-onset colorectal cancer. *Cancer Discovery*. (2023) 13:570–9. doi: 10.1158/2159-8290.CD-22-0764

15. Venugopal A, Carethers JM. Epidemiology and biology of early onset colorectal cancer. *EXCLI J.* (2022) 21:162–82. doi: 10.17179/excli2021-4456

16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71

17. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. *Acta Oncol.* (2014) 53:852–64. doi: 10.3109/0284186X.2014.895036

18. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. (2010) 28:4706–13. doi: 10.1200/JCO.2009.27.6055

19. Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, et al. KRAS and BRAF mutations in stage II and III colon cancer: A systematic review and metaanalysis. J Natl Cancer Inst. (2022) 114:517–27. doi: 10.1093/jnci/djab190

20. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, et al. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. *Ann Oncol.* (2016) 27:1746–53. doi: 10.1093/annonc/mdw261

21. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol.* (2010) 11:753–62. doi: 10.1016/S1470-2045(10)70130-3

22. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. *Int J Cancer.* (2015) 136:83–90. doi: 10.1002/ijc.v136.1

23. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. *J Clin Oncol.* (2017) 35:2624–30. doi: 10.1200/JCO.2016.71.4394

24. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic

colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. *Int J Cancer*. (2013) 133:1914–25. doi: 10.1002/ijc.v133.8

25. Tan ES, Fan W, Knepper TC, Schell MJ, Sahin IH, Fleming JB, et al. Prognostic and predictive value of PIK3CA mutations in metastatic colorectal cancer. *Target Oncol.* (2022) 17:483–92. doi: 10.1007/s11523-022-00898-7

26. Wu S, Gan Y, Wang X, Liu J, Li M, Tang Y. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. *J Cancer Res Clin Oncol.* (2013) 139:891–900. doi: 10.1007/s00432-013-1400-x

27. Salvatore L, Calegari MA, Loupakis F, Fassan M, Di Stefano B, Bensi M, et al. PTEN in colorectal cancer: shedding light on its role as predictor and target. *Cancers (Basel)*. (2019) 11:E1765. doi: 10.3390/cancers11111765

28. Molinari F, Frattini M. Functions and regulation of the PTEN gene in colorectal cancer. *Front Oncol.* (2013) 3:326. doi: 10.3389/fonc.2013.00326

29. Liebl MC, Hofmann TG. The role of p53 signaling in colorectal cancer. *Cancers* (*Basel*). (2021) 13:2125. doi: 10.3390/cancers13092125

30. Wang C, Ouyang C, Cho M, Ji J, Sandhu J, Goel A, et al. Wild-type APC is associated with poor survival in metastatic microsatellite stable colorectal cancer. *Oncologist.* (2021) 26:208–14. doi: 10.1002/onco.13607

31. Jorissen RN, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, et al. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. *Br J Cancer.* (2015) 113:979–88. doi: 10.1038/bjc.2015.296

32. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. *Int J Colorectal Dis.* (2007) 22:491–7. doi: 10.1007/s00384-006-0192-8

33. Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. *Clin Colorectal Cancer*. (2018) 17:198–205. doi: 10.1016/j.clcc.2018.05.006

34. Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. *Oncologist.* (2019) 24:1395–402. doi: 10.1634/theoncologist.2018-0785

35. Marks KM, West NP, Morris E, Quirke P. Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. *Br J Surg.* (2018) 105:e99–109. doi: 10.1002/bjs.10756

36. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. *Mod Pathol*. (2003) 16:376–88. doi: 10.1097/01.MP.0000062859.46942.93

37. Luo ZW, Zhu MG, Zhang ZQ, Ye FJ, Huang WH, Luo XZ. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. *BMC Cancer.* (2019) 19:123. doi: 10.1186/s12885-019-5324-y

38. Nitsche U, Zimmermann A, Späth C, Müller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. *Ann Surg.* (2013) 258:775–82. doi: 10.1097/SLA.0b013e3182a69f7e

39. An Y, Zhou J, Lin G, Wu H, Cong L, Li Y, et al. Clinicopathological and molecular characteristics of colorectal signet ring cell carcinoma: A review. *Pathol Oncol Res.* (2021) 27:1609859. doi: 10.3389/pore.2021.1609859

40. Diao Z, Han Y, Chen Y, Zhang R, Li J. The clinical utility of microsatellite instability in colorectal cancer. *Crit Rev Oncol Hematol.* (2021) 157:103171. doi: 10.1016/j.critrevonc.2020.103171

41. Rhee YY, Kim KJ, Kang GH. CpG island methylator phenotype-high colorectal cancers and their prognostic implications and relationships with the serrated neoplasia pathway. *Gut Liver*. (2017) 11:38–46. doi: 10.5009/gnl15535

42. Idos GE, Kwok J, Bonthala N, Kysh L, Gruber SB, Qu C. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: A systematic review and meta-analysis. *Sci Rep.* (2020) 10:3360. doi: 10.1038/s41598-020-60255-4

43. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res.* (2009) 15:6412–20. doi: 10.1158/1078-0432.CCR-09-1438

44. Valenzuela G, Canepa J, Simonetti C, Solo de Zaldívar L, Marcelain K, González-Montero J. Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach. *World J Clin Oncol.* (2021) 12:1000–8. doi: 10.5306/wjco.v12.i11.1000

45. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC Public Health*. (2013) 13:154. doi: 10.1186/1471-2458-13-154

46. Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, et al. Impact of patient age on molecular alterations of left-sided colorectal tumors. *Oncologist.* (2019) 24:319–26. doi: 10.1634/theoncologist.2018-0117

47. Tenny S, Hoffman MR. Odds ratio. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing. (2024) Available at: http://www.ncbi.nlm.nih.gov/books/NBK431098/.

48. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. (2011) 342:d549. doi: 10.1136/bmj.d549 49. Wang MJ, Ping J, Li Y, Adell G, Arbman G, Nodin B, et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. *Sci Rep.* (2015) 5:10645. doi: 10.1038/srep10645

50. Du M, Gu D, Xin J, Peters U, Song M, Cai G, et al. Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. *Cell Rep Med.* (2023) 4:100974. doi: 10.1016/j.xcrm.2023.100974

51. Ugai T, Väyrynen JP, Lau MC, Borowsky J, Akimoto N, Väyrynen SA, et al. Immune cell profiles in the tumor microenvironment of early-onset, intermediateonset, and later-onset colorectal cancer. *Cancer Immunol Immunother*. (2022) 71:933– 42. doi: 10.1007/s00262-021-03056-6

52. Gardner IH, Siddharthan R, Watson K, Dewey E, Ruhl R, Khou S, et al. A distinct innate immune signature of early onset colorectal cancer. *Immunohorizons.* (2021) 5:489–99. doi: 10.4049/immunohorizons.2000092

53. Irabor DO, Oluwasola OA, Ogunbiyi OJ, Ogun OG, Okolo CA, Melas M, et al. Microsatellite instability is common in colorectal cancer in native Nigerians. *Anticancer Res.* (2017) 37:2649–54. doi: 10.21873/anticanres

54. Li GM, Xiao GZ, Qin PF, Wan XY, Fu YJ, Zheng YH, et al. Single-cell RNA sequencing reveals heterogeneity in the tumor microenvironment between young-onset and old-onset colorectal cancer. *Biomolecules*. (2022) 12:1860. doi: 10.3390/biom12121860

55. Pilozzi E, Maresca C, Duranti E, Giustiniani MC, Catalanotto C, Lucarelli M, et al. Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences. *Am J Clin Pathol.* (2015) 143:374–84. doi: 10.1309/AJCPNOC55IOLXFUD

56. Andric F, Al-Fairouzi A, Wettergren Y, Szeponik L, Bexe-Lindskog E, Cusack JC, et al. Immune microenvironment in sporadic early-onset versus average-onset colorectal cancer. *Cancers (Basel).* (2023) 15:1457. doi: 10.3390/cancers15051457

57. Lu C, Zhang X, Schardey J, Wirth U, Heinrich K, Massiminio L, et al. Molecular characteristics of microsatellite stable early-onset colorectal cancer as predictors of prognosis and immunotherapeutic response. *NPJ Precis Oncol.* (2023) 7:63. doi: 10.1038/s41698-023-00414-8

58. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, et al. Clinical and molecular characterization of early-onset colorectal cancer. *Cancer.* (2019) 125:2002–10. doi: 10.1002/cncr.31994

59. Ha YJ, Shin YJ, Tak KH, Park JL, Kim JH, Lee JL, et al. Reduced expression of alanyl aminopeptidase is a robust biomarker of non-familial adenomatous polyposis and non-hereditary nonpolyposis colorectal cancer syndrome early-onset colorectal cancer. *Cancer Med.* (2023) 12:10091–104. doi: 10.1002/cam4.5675

60. Yang J, Zhao Y, Yuan R, Wang Y, Wang S, Chang Z, et al. Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer. *Eur J Med Res.* (2023) 28:533. doi: 10.1186/s40001-023-01491-y

61. Furuhashi S, Bustos MA, Mizuno S, Ryu S, Naeini Y, Bilchik AJ, et al. Spatial profiling of cancer-associated fibroblasts of sporadic early onset colon cancer microenvironment. *NPJ Precis Oncol.* (2023) 7:118. doi: 10.1038/s41698-023-00474-w

62. Chang SH, Patel N, Du M, Liang PS. Trends in early-onset vs late-onset colorectal cancer incidence by race/ethnicity in the United States cancer statistics database. *Clin Gastroenterol Hepatol.* (2022) 20:e1365-77. doi: 10.1016/j.cgh.2021.07.035

63. Wang R, Wang MJ, Ping J. Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: A population-based cohort study of SEER 9 registries data (1988-2011). *Med (Baltimore)*. (2015) 94:e1402. doi: 10.1097/MD.00000000001402

64. McClelland PHT, Liu T, Ozuner G. Early-onset colorectal cancer in patients under 50 years of age: demographics, disease characteristics, and survival. *Clin Colorectal Cancer*. (2022) 21:e135–44. doi: 10.1016/j.clcc.2021.11.003

65. Saraiva MR, Rosa I, Claro I. Early-onset colorectal cancer: A review of current knowledge. World J Gastroenterol. (2023) 29:1289–303. doi: 10.3748/wjg.v29.i8.1289

66. Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, et al. Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines. *Clin Gastroenterol Hepatol.* (2023) 21:581–603. doi: 10.1016/j.cgh.2022.12.006

67. Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. *JAMA Surg.* (2015) 150:402–9. doi: 10.1001/jamasurg.2014.3572

68. Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. *Cancer*. (2016) 122:929–34. doi: 10.1002/cncr.29716

69. Kanter K, Fish M, Mauri G, Horick NK, Allen JN, Blaszkowsky LS, et al. Care patterns and overall survival in patients with early-onset metastatic colorectal cancer. *JCO Oncol Pract.* (2021) 17:e1846–55. doi: 10.1200/OP.20.01010

70. NCCN. Guidelines Detail (2023). Available online at: https://www.nccn.org/guidelines/guidelines-detail.

71. Afrăsânie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Păduraru M, Adavidoaiei AM, et al. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. *Radiol Oncol.* (2019) 53:265–74. doi: 10.2478/raon-2019-0033

72. Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with

leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: A *post hoc* analysis of the PETACC-8 trial. *JAMA Oncol.* (2016) 2:643–53. doi: 10.1001/jamaoncol.2015.5225

73. Jácome AA, Vreeland TJ, Johnson B, Kawaguchi Y, Wei SH, Nancy You Y, et al. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. *Br J Cancer.* (2021) 124:797–804. doi: 10.1038/s41416-020-01169-w

74. Aljehani MA, Bien J, Lee JSH, Fisher GA, Lin AY. KRAS sequence variation as prognostic marker in patients with young- vs late-onset colorectal cancer. *JAMA Netw Open*. (2023) 6:e2345801. doi: 10.1001/jamanetworkopen.2023.45801

75. Khan SA, Morris M, Idrees K, Gimbel MI, Rosenberg S, Zeng Z, et al. Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. *J Pediatr Surg.* (2016) 51:1812–7. doi: 10.1016/j.jpedsurg.2016.07.015

76. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, et al. NRAS mutations are rare in colorectal cancer. *Diagn Mol Pathol.* (2010) 19:157–63. doi: 10.1097/PDM.0b013e3181c93fd1

77. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. *Int J Cancer.* (2013) 133:1624–30. doi: 10.1002/ijc.28183

78. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. *Biochim Biophys Acta*. (2015) 1855:104–21. doi: 10.1016/j.bbcan.2014.09.008

79. Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. *Gastroenterol Rep (Oxf).* (2020) 8:179–91. doi: 10.1093/gastro/goaa026

80. Nakayama M, Oshima M. Mutant p53 in colon cancer. J Mol Cell Biol. (2019) 11:267–76. doi: 10.1093/jmcb/mjy075

81. Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The role of p53 dysfunction in colorectal cancer and its implication for therapy. *Cancers (Basel).* (2021) 13:2296. doi: 10.3390/cancers13102296

82. Aghabozorgi AS, Bahreyni A, Soleimani A, Bahrami A, Khazaei M, Ferns GA, et al. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. *Biochimie*. (2019) 157:64–71. doi: 10.1016/j.biochi.2018.11.003

83. Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. *Genes Dev.* (2021) 35:787-820. doi: 10.1101/gad.348226.120

 Sinicrope FA. Lynch syndrome-associated colorectal cancer. N Engl J Med. (2018) 379:764–73. doi: 10.1056/NEJMcp1714533

85. McRonald FE, Pethick J, Santaniello F, Shand B, Tyson A, Tulloch O, et al. Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathway. *Eur J Hum Genet.* (2024). doi: 10.1038/s41431-024-01550-w

86. Mezzapesa M, Losurdo G, Celiberto F, Rizzi S, d'Amati A, Piscitelli D, et al. Serrated colorectal lesions: an up-to-date review from histological pattern to molecular pathogenesis. *Int J Mol Sci.* (2022) 23:4461. doi: 10.3390/ijms23084461

87. Barresi V, Reggiani Bonetti L, Ieni A, Caruso RA, Tuccari G. Histological grading in colorectal cancer: new insights and perspectives. *Histol Histopathol.* (2015) 30:1059–67. doi: 10.14670/HH-11-633

88. Fadel MG, Malietzis G, Constantinides V, Pellino G, Tekkis P, Kontovounisios C. Clinicopathological factors and survival outcomes of signet-ring cell and mucinous carcinoma versus adenocarcinoma of the colon and rectum: a systematic review and meta-analysis. *Discovery Oncol.* (2021) 12:5. doi: 10.1007/s12672-021-00398-6

89. Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. *Cancer Commun (Lond)*. (2019) 39:13. doi: 10.1186/ s40880-019-0361-0

90. Gabriel E, Attwood K, Al-Sukhni E, Erwin D, Boland P, Nurkin S. Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol. (2018) 9:96–110. doi: 10.21037/jgo

91. Ding X, Yang X, Wu D, Huang Y, Dai Y, Li J, et al. Nomogram predicting the cancer-specific survival of early-onset colorectal cancer patients with synchronous liver metastasis: a population-based study. *Int J Colorectal Dis.* (2022) 37:1309–19. doi: 10.1007/s00384-022-04175-x

92. Chen Y, He L, Lu X, Tang Y, Luo G, Chen Y, et al. Causes of death among earlyonset colorectal cancer population in the United States: a large population-based study. *Front Oncol.* (2023) 13:1094493. doi: 10.3389/fonc.2023.1094493

93. Benesch MGK, Mathieson A, O'Brien SBL. Effects of tumor localization, age, and stage on the outcomes of gastric and colorectal signet ring cell adenocarcinomas. *Cancers (Basel).* (2023) 15:714. doi: 10.3390/cancers15030714

94. De Renzi G, Gaballo G, Gazzaniga P, Nicolazzo C. Molecular biomarkers according to primary tumor location in colorectal cancer: current standard and new insights. *Oncology*. (2021) 99:135–43. doi: 10.1159/000510944

95. Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, et al. Analysis of survival among adults with early-onset colorectal cancer in the national cancer database. *JAMA Netw Open.* (2021) 4:e2112539. doi: 10.1001/jamanetworkopen.2021.12539

96. Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, et al. KRAS testing, tumor location, and survival in patients with stage IV colorectal cancer: SEER 2010-2013. J Natl Compr Canc Netw. (2017) 15:1484–93. doi: 10.6004/jnccn.2017.7011

97. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. *BMC Gastroenterol.* (2019) 19:46. doi: 10.1186/s12876-019-0965-5

98. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Canc Netw. (2017) 15:411–9. doi: 10.6004/jnccn.2017.0038

99. Foppa C, Tamburello S, Maroli A, Carvello M, Poliani L, Laghi L, et al. Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients. *Eur J Surg Oncol.* (2022) 48:857–63. doi: 10.1016/j.ejso.2021.10.021

100. Laskar RS, Ghosh SK, Talukdar FR. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics. *Mol Carcinog.* (2015) 54:1786–95. doi: 10.1002/mc.22250

101. Perea J, García JL, Corchete L, Tapial S, Olmedillas-López S, Vivas A, et al. A clinico-pathological and molecular analysis reveals differences between solitary (early and late-onset) and synchronous rectal cancer. *Sci Rep.* (2021) 11:2202. doi: 10.1038/ s41598-020-79118-z

102. Spolverato G, Fassan M, Scarpa M, Stepanyan A, De Simoni O, Scognamiglio F, et al. IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancer. *Br J Surg.* (2023) 110:1490–501. doi: 10.1093/bjs/znad219

103. Ugai T, Haruki K, Harrison TA, Cao Y, Qu C, Chan AT, et al. Molecular characteristics of early-onset colorectal cancer according to detailed anatomical locations: comparison with later-onset cases. *Am J Gastroenterol.* (2023) 118:712-26. doi: 10.14309/ajg.00000000002171

104. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. *Gastroenterol Res.* (2018) 11:264–73. doi: 10.14740/gr1062w

105. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science*. (2006) 313:1960–4. doi: 10.1126/science.1129139

106. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. *Clin Cancer Res.* (2020) 26:332–9. doi: 10.1158/1078-0432.CCR-18-1851

107. Ten Hoorn S, de Back TR, Sommeijer DW, Vermeulen L. Clinical value of consensus molecular subtypes in colorectal cancer: A systematic review and metaanalysis. J Natl Cancer Inst. (2022) 114:503–16. doi: 10.1093/jnci/djab106